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Abstract
After an episode of repetitive mild traumatic brain injury (rmTBI), many cellular and
molecular cascades are initiated that result in the disruption of the structural and chemical
integrity of the components in the brain, leading to the development of various cognitive
deficits. The goal of this thesis was to evaluate a mouse model of concussion in order to
study the relationship between rmTBI, GSK3β and tau phosphorylation, and behavioural
outcomes in a transgenic mouse line expressing solely human tau. We found that there was
increased phosphorylation of the two main regulatory sites on GSK3β, Tyr216 and Ser9, in
the C57BL/6 mice. When investigating the pathology and behaviour in the MAPT KI mice,
there was positive silver staining, pathological tau staining (AT8), and increased Iba1
staining compared to shams, with animals displaying cognitive deficits upon behavioural
testing. Overall, this study supports the use of MAPT KI transgenic mice in rmTBI studies.
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Encephalopathy (CTE), tauopathy, glycogen synthase kinase 3 (GSK3), glycogen synthase
kinase 3-beta (GSK3β), tau, MAPT KI mice
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Summary for Lay Audience
Traumatic brain injuries (TBIs) are injuries that affect the structural integrity of the brain
which, in turn, has a negative impact on brain functions and influences the behaviour of those
affected. The least severe form of TBIs, known as mild TBIs (mTBIs) includes concussions
and sub-concussive closed head injuries. When the exposure to mTBIs becomes repetitive,
in other words repetitive mild traumatic brain injuries (rmTBI), there is an increased risk for
the development of a neurodegenerative disease known as Chronic Traumatic
Encephalopathy (CTE). The main characteristic of this disease is the presence of abnormal
tau protein aggregates in the brain. One protein that has been implicated in the process of
formation of these abnormal protein aggregates is called glycogen synthase kinase 3-beta
(GSK3β).
There is always the struggle of taking results from scientific studies involving animal models
and then applying them to human beings.

However, technological advancements have

allowed the development of genetic tools that have been applied to rodents in order to create
ideal models with greater clinical relevance to human disease. In this thesis I investigate a
novel mouse model in which the entire mouse tau gene has been replaced with the human tau
gene. I use this mouse model to characterize the structural damage, at the cellular and
molecular levels, that occur post-rmTBI, as well as the behavioural outcomes, in order to
validate the use of this model in future research.
This study demonstrates that the novel mouse model is capable of developing the cellular
and molecular injuries typical of rmTBIs. The mice also demonstrate behavioural deficits
that correlate with rmTBI injury, similar to that seen in humans. Overall, this study supports
the use of these mice for future rmTBI studies, as these mice are more clinically relevant and
therefore more desirable models. This study will hopefully serve as a stepping stone for
future studies of rmTBI with a focus on further characterizing the pathology and developing
and applying potential therapeutics.
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Chapter 1
1

Introduction

After an episode of repetitive mild traumatic brain injury (rmTBI), also referred to as
concussions, many cascades are initiated that result in the deterioration of neurons,
leading to degeneration within the brain and the development of cognitive deficits.
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that develops
from repetitive impacts sustained to the head causing concussions (Lucke-Wold et al.,
2014). This has been observed in both athletes, those in contact sports, and military
personnel (Lucke-Wold et al., 2014). It is characterized as a tauopathy as one of the
major defining features of the disease involves tau, a microtubule-associated protein.
Abnormally phosphorylated tau within neurons begins to form aggregates, fibrils, and
tangles, which disrupts normal cell functions such as microtubule assembly and the
ability to maintain stable structure within the cell (Kolarova et al, 2012). Abnormal
phosphorylation of tau not only causes pathology within neurons, but it also results in
cognitive impairments due to the degeneration within the brain itself (Kolarova et al,
2012).

This leads to progressive cognitive impairments/dementia such as memory

deficits, depression, and increased anxiety/anxiety related behaviours (Luo et al., 2014),
observed in CTE.

I sought to develop a clinically relevant mouse model of

concussion/rmTBI to study the pathophysiological mechanisms that lead to CTE. One
mechanism that has been put forward to explain the development of CTE following
rmTBI focuses on the tau kinase, glycogen synthase kinase 3-beta (GSK3β) (Dash et al.,
2011; Moszczynski et al., 2018). It has been proposed that GSK3β is responsible for the
abnormal phosphorylation of tau in tauopathies, such as CTE (Hooper, Killick, and
Lovestone, 2008). This abnormal phosphorylation of tau is what leads to the pathological
formation of aggregates/fibrils/tangles leading to neuronal death (Polydoro et al., 2009).
A model of concussion needs to mimic the tell-tale features of human injury including the
cellular pathologies, molecular pathologies, and behavioural outcomes post-injury. The
accumulation of all of these features is what ultimately leads to the eventual development
of CTE. It is the goal of this thesis to develop and evaluate a mouse model of concussion
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in order to study the relationship between rmTBI, GSK3β activity, tau phosphorylation
and the development of cognitive deficits in a transgenic mouse line expressing solely
human tau.

1.1

Concussion

Traumatic Brain Injuries (aka Primary Injuries)
Traumatic brain injuries (TBIs) are a devastating set of injuries that affect the structural
and chemical integrity of the brain which, in turn, influences the behaviour of those
affected (Bramlett & Dietrich, 2015; Kokiko-Cochran et al., 2018; Shultz et al., 2020).
When severe, TBIs affect the rest of the central nervous system and cause permanent
damage to the brain or even death (Ling et al., 2015). TBIs have recently become of
more interest due to the increasing awareness of the general public, as they are a huge
health concern (Yap et al., 2017). The complications that arise, post-TBI, create a ripple
effect in the health care system, the economy, and cause strain in those closest to the
individuals who are injured (Siebold et al., 2018). Anyone can be affected by a TBI,
however, some individuals are more at risk than others. Individuals who partake in
contact sports, are enrolled in the military, or have careers that increase the probability of
injury, are all examples of individuals that are at a higher risk of incurring a TBI (McKee
et al., 2009).
TBIs may be classed based on their severity as mild, moderate or severe. Several clinical
assessment tools have been developed and used in order to assess the severity of a
sustained TBI including various imaging techniques, timing and/or presence of loss of
consciousness, presence and/or absence of amnesia, and finally the Glasgow Coma Scale
(Siebold et al., 2018). The least severe classification of TBIs, known as mild TBI
(mTBI), includes injuries referred to as concussions and sub-concussive injuries, which
involve acceleration, deceleration and rotational mechanical forces transmitted to the
brain upon impact resulting in shearing of brain tissues (Montenigro et al., 2017).
Concussions and sub-concussive injuries are typically closed head injuries which do not
involve penetrating forces (Tagge et al., 2018). Specifically, concussions can be defined
as any impact that directly or indirectly involves the head producing a number of
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symptoms which can recover over a variable length of time, depending on the
individuals’ circumstance (Montenigro et al., 2017). However, sub-concussions can be
defined similarly to that of concussions, with the exception that sub-concussions fail to
produce visible symptoms (Bailes et al., 2013; Erlanger, 2015; Montenigro et al., 2017).
When repetitive, the pathological sequelae of rmTBIs can accumulate and activate
secondary injury cascades and potentially the development of neurological disease
(Bailes et al., 2013).
There are many external factors that influence the severity of an mTBI. It has been
proposed that acceleration and deceleration forces play an important role in the outcome
of the severity of injury (Ling et al., 2015). These forces can act on the brain either in a
linear or non-linear/rotational manner, depending on the mechanism or method of
delivery for the injury (Ling et al., 2015). The result is the brain, consisting of all of the
neurons, glia cells, and other components, being mechanically disarrayed (Ling et al.,
2015). The location of the insult, the magnitude of the force behind the injury, the
amount of surface area affected, and the amount of freedom of the head to move during
impact are also factors to consider (Bolton-Hall et al., 2019).
There are instances in which individuals experience more than one mTBI in a given
period of time, referred to as repetitive/repeated mild traumatic brain injury (Donovan et
al., 2014). Repetitive mTBI can potentially lead to the development of second-impact
syndrome (SIS) (Cobb & Battin, 2004) in which there can be serious consequences
including death. It has been shown that there is a window of time in which the brain is
more vulnerable to a second potential impact after the initial injury (Laurer et al., 2001;
Longhi et al., 2005) contributing to the development of SIS. With each injury, the
pathological cascades and behavioural symptoms become additive (Cobb & Battin,
2004).
TBI is often described as having two components: a primary injury and a secondary
injury. The primary injury/TBI involves the physical disruption of the brain and includes
various mechanical disruptions such as the shearing and stretching of axons (Cernak et
al., 2004). However, not all primary injuries/TBIs are the same and this makes treatment
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difficult as the nature of these injuries are very heterogenous (Siebold et al., 2018;
Washington et al., 2012).

The primary injury/TBI initiates many secondary injury

cascades, such as, diffuse axonal injury, apoptosis, and ionic disturbances (Cernak et al.,
2004). The intensity and duration of these secondary injury cascades depends ultimately
on the severity of the initial injury.
Secondary Injuries
Secondary injuries are considered to be any and all pathological cascades that occur after
the initial insult to the brain (Cernak et al., 2004). Secondary injuries can roughly be
sorted into two major categories: secondary cellular injuries and secondary molecular
injuries, which both lead to the development of behavioural deficits (Krishnamurthy K &
Laskowitz DT, 2016; Washington et al., 2012). It is worthy to note that certain cases of
cellular injury, such as immediate cell death or direct damage to brain tissues, can be
considered by some to be primary injuries as they are a result originating directly from
the impact (Abdul-Muneer et al., 2015). Behavioural outcomes, on the other hand, are a
result of the additive effects of both the secondary cellular and molecular injuries
produced from the initial trauma (T. Chen et al., 2011; Davis, 2000).
Secondary Cellular Injuries
Secondary cellular injuries result in mechanical damage to the various structures within
the brain (J. R. Hay et al., 2015), as well as damage to cells and/or organelles within the
central nervous system (Haber et al., 2017; Mbye et al., 2008). There have been several
studies that have investigated the effect of TBIs on the integrity of the blood brain barrier
(BBB) post-injury (J. R. Hay et al., 2015; Tomkins et al., 2011; Weissberg et al., 2014).
Interestingly, one study investigating the effects of concussive and sub-concussive
impacts on football players found that there was increased BBB permeability in both the
gray and white matter areas in approximately 40% of the players that were analyzed
(Weissberg et al., 2014). The authors postulated that this could be influenced by repeated
exposures to sub-concussive events that go unnoticed at the time of the injury, or due to
neglected or unreported concussive events (Weissberg et al., 2014). The vasculature
within the brain is also at risk post-injury, as mTBIs cause damage to the blood vessels as
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a whole and microstructural damage to the vascular cells which decreases and alters
blood flow and brain function (Jullienne et al., 2016; Monson et al., 2019). Depending
on the severity of the TBI, the location of the injury and the method of delivery, a
beneficial or a harmful/prolonged inflammatory response may develop (Burda et al.,
2016).

With the integrity of the BBB being compromised post-TBI, there is the

possibility of the inflammatory response to be sustained by incoming neutrophils,
monocytes, and lymphocytes (Ziebell & Morganti-Kossmann, 2010).
The mechanical forces of TBIs also cause stretching, shearing and/or tearing of the
neurons and axons of neurons within the brain which, in turn, results in diffuse axonal
injuries (DAI) throughout the white matter (Yap et al., 2017). DAI is considered to be a
hallmark of TBIs and is of great concern as it results in the disruption of axonal transport,
production of retraction bulbs, and in more severe cases, axonal loss and degeneration
(Haber et al., 2017).

It was discovered that even under very mild axonal stretch

conditions there was increased growth cone collapse and smaller growth cones within the
tips of regenerative sprouts in developing axons (Yap et al., 2017). Another study,
investigating the relationship between diffusion tensor imaging (DTI) and DAI in a
Closed-Head Impact Model of Engineered Rotational Acceleration (CHIMERA) mouse
model of TBI, discovered that there were DTI abnormalities, post-injury, indicating
damage to several white matter tracts such as the optic tract and the corpus callosum
(Haber et al., 2017). Silver staining of sections from injured brains was used to confirm
the findings of the DTI results. Unfortunately, when cellular damage occurs it can result
in various components within the cell to be damaged as well. Organelles, in particular
the mitochondria which are essential to neuronal function, are also subject to injury upon
TBI (Mbye et al., 2008). Upon injury, many cascades are thrown into disarray (such as
Ca2+ homeostasis, activation of calpains and caspases, increases in oxidative stress),
which results in mitochondrial dysregulation, and ultimately neuronal death (G. Cheng et
al., 2012). All of these examples of cellular injury due to TBIs, and many more, are
intimately related to various secondary molecular injuries that are initiated post-injury.
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Secondary Molecular Injuries
There are many molecular cascades and pathways that are activated post-TBI that are
classified as secondary molecular injuries such as the generation of reactive oxygen
species (ROS)/reactive nitrogen species (RNS), proapoptotic signals, activation of
various enzymes, and production of inflammatory signals (Bramlett & Dietrich, 2015),
and many more. TBIs create an environment in which the balance of antioxidants and the
generation of ROS/RNS becomes altered, favouring the production of the latter, thus
resulting in oxidative stress (Abdul-Muneer et al., 2015). The production of these free
radicals, in this case ROS/RNS, poses a serious threat to the maintenance of cellular
homeostasis as these radicals are capable of interacting and reacting with any cellular
components, therefore compromising cellular function (Tyurin et al., 2000). Oxidative
stresses play a role in a number of other secondary injury processes, both cellular and
molecular. Oxidative stress has been implicated in the increased permeability of the BBB
and brain vasculature, further facilitating inflammation by directly/indirectly initiating the
production of various neuroinflammatory signals, and damage to proteins, DNA, and
mitochondrial function (Abdul-Muneer et al., 2015; Ansari et al., 2008).
Apoptosis, a form of programmed cell death, can be an early or delayed post-injury
response that ultimately results in neuronal death (Uzan et al., 2006; X. Zhang et al.,
2004). The initiation of apoptosis can occur via a number of different pathways, all of
which able to interact with one another (X. Zhang et al., 2004) to result in the completion
of apoptosis. One method of apoptosis induction is through the activation of caspases, a
family of proteases, initiated through intrinsic and/or extrinsic routes. Intrinsic activation
signals consist of various stress signals from mitochondria contained within the cell,
however, extrinsic signals consist of a number of signals binding to their respective
receptors (Uzan et al., 2006).

Both intrinsic and extrinsic pathways initiate the

proteolytic cleavage of members of the caspase family which allow the enzymes to be
able to interact with their substrates, resulting in DNA fragmentation, cytoskeletal
disintegration, and ultimately apoptosis (X. Zhang et al., 2004). Another method of
regulation for the process of apoptosis is through the balance of members of the B-cell
lymphoma-2 (Bcl-2) family. The Bcl-2 family consists of both pro- and anti- cell death
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signals, and the balance of these signals influence whether or not apoptosis will occur
(Wong et al., 2005). Events, such as TBIs, can tip the scales in favour of apoptosis
through the activation/imbalance of any of these pathways resulting not only in neuronal
death, but the death of various glial cells as well (X. Zhang et al., 2004).
Once a TBI has occurred, there are many molecular pathways that are involved in the
inflammatory process that are activated and are able to influence various cellular changes
that occur throughout the inflammatory response (Ghirnikar et al., 1998). Some of these
pathways include the release of several mediators such as prostaglandins, free radicals
(ROS/RNS), and cytokines which facilitate the expression of chemokines (Ghirnikar et
al., 1998). The production and levels of cytokines and chemokines play a role in the
neuropathological outcome after TBIs. There is controversy surrounding the therapeutic
value of inflammation post-injury, due to the fact that inflammation can benefit the
central nervous system by clearing out damaged cells and debris, while a pro-longed
inflammatory response can be detrimental (Morganti-Kossmann et al., 2001).

In

particular, cytokines involved in the inflammatory process can be divided into two
subgroups, one being cytokines with pro-inflammatory properties and the other being
cytokines with anti-inflammatory properties (T. Chen et al., 2011).

One study

investigating the effects of administration of salvianolic acid B (SalB) on TBI found that
SalB blocked the activities of pro-inflammatory cytokines, thus preventing the infiltration
of incoming inflammatory cells while increasing the expression of anti-inflammatory
cytokines (T. Chen et al., 2011).

The treatment with SalB resulted in various

improvements post-TBI in the form of decreased lesion volumes, brain edema, and
behavioural deficits with decreases in motor functional and spatial learning/memory
impairments (T. Chen et al., 2011).
Behavioural Outcomes
There are many cognitive, behavioural, and emotional conditions that arise postTBI/TBIs due to the accumulated actions of secondary cellular and molecular injury
processes (Davis, 2000; Washington et al., 2012). The intensity, the number, and the
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nature of the TBIs can influence the prevalence of these conditions post-injury
(Washington et al., 2012).
The most common behavioural outcome occurring after TBIs is the development of
depression, with a higher percentage of individuals developing some level of depression
post-injury compared to anxiety (Leong Bin Abdullah et al., 2018; Mauri et al., 2014).
One study investigating the prevalence of Axis I and II disorders (mental
health/substance use disorders versus personality/mood disorders), post-TBI, discovered
that the development of major depression was present at both the acute and chronic time
points of the study, all the way up to the 30 year follow up checkpoint (Koponen et al.,
2002). The onset of depression post-TBI can be attributed to the damage from the initial
injury itself, various secondary injury pathways (example: decreased glucose
metabolism), and external lifestyle factors (Fann et al., 2009). There is a possibility that
individuals who experience TBIs, and develop depression, can also develop anxiety as
well, on top of the depression, making treatment even more difficult (Barker-Collo et al.,
2018).
Anxiety disorders are another common behavioural outcome after TBIs. There is an
increased risk for the development of several anxiety disorders post-injury including
generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), panic
disorder, and others (Hiott & Labbate, 2002).

In one study, the authors sought to

investigate anxiety/anxiety-like behaviours in a rodent mild blast TBI model and aimed to
correlate the behavioural outcomes to possible changes at the genetic level (Blaze et al.,
2020). In this study there were significant increases in anxiety/anxiety-like behaviour at
the acute time points studied and, while not statistically significant, there was a trend
towards increased anxiety at chronic time points. This study also showed that there were
significant changes in gene expression in the amygdala post-TBI at chronic time points
by transcriptomic analyses (Blaze et al., 2020). Other reports have indicated changes in
the structural features of the amygdala as well as differences in various molecular
processes, such as levels of mRNA and protein expression (Almeida-Suhett et al., 2014;
Tate et al., 2016).
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The relationship between TBIs and posttraumatic stress disorder (PTSD) is both
controversial and complex (Y.-F. Chen & Zhao, 2019). Scientists have proposed that in
some circumstances TBIs, in particular mTBIs/rmTBIs, can be an important risk factor
for the development of this anxiety disorder (Hoge et al., 2008). This could be in large
part due to the fact that individuals who suffer mTBIs/rmTBIs in a traumatic scenario are
able to remember the traumatic event due to lack of loss of consciousness and are more
likely to develop PTSD (Gil et al., 2005). Situations that typically give rise to PTSD
tend to also involve the potential for incurring TBIs, such as active military personnel or
abuse victims (Y.-F. Chen & Zhao, 2019). Both TBIs and PTSD lead to the development
of several undesirable and harmful behavioural traits including depression, violence,
substance abuse, and suicidal tendencies (Y.-F. Chen & Zhao, 2019).
Cognition, memory, and learning processes are all negatively affected by TBIs. There is
decreased spatial information processing, and decreased learning and memory
processing, all of which are dependent on the hippocampus (Pierce et al., 1998; Rola et
al., 2006). There are many underlying pathological pathways that are initiated, post-TBI,
that could play a role in the cognitive/learning/memory deficits observed. In particular,
one study looking into the effects of TBIs on neurogenesis in the hippocampus found
evidence of cell loss/death, changes in cell fates, and evidence of persisting inflammation
(Rola et al., 2006). Another study revealed that TBI increases the production of ROS
(corresponding to oxidative stress) and decreases antioxidant and synaptic protein levels
(Ansari et al., 2008), most likely contributing to cellular dysfunction/cell death in the
hippocampus and behavioural deficits. Overall, the nature of TBIs is quite heterogeneous
as is the patient population therefore making behavioural deficits difficult to predict.
Outcomes Post-Concussion
Ultimately there are four possible outcomes after an episode(s) of TBI. First, a concussed
individual can have symptoms acutely that then resolve within days or weeks (Alexander,
1995). Second, a concussed individual may develop post-concussive syndrome (PCS), in
which the symptoms take longer, months or even years, to resolve (Maroon et al., 2012).
PCS is a very complex phenomenon in which the composition of symptoms can vary
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within the same individual over time (Maroon et al., 2012).

Third, an unfortunate

subgroup of concussed individuals may go on to develop a neurodegenerative disease
known as Chronic Traumatic Encephalopathy (CTE) (McKee et al., 2013). Concussions
have been shown to be a risk factor for the development of CTE in several studies
(McKee et al., 2009, 2013; Roberts et al., 1990). There is also a possibility to further
develop other neurodegenerative characteristics or diseases alongside CTE such as CTE
with Alzheimer’s Disease (AD) (Turner et al., 2016; Yuan & Wang, 2018), CTE with
Amyotrophic Lateral Sclerosis (ALS) (Moszczynski et al., 2018; Walt et al., 2018), and
CTE with other pathological protein deposits, such as transactive response DNA-binding
protein of 43 kDa (TDP-43) (Heyburn et al., 2019; McKee et al., 2010). The fourth
possible outcome after TBI is death, either from complications post-injury, SIS (Cobb &
Battin, 2004), and eventual death from the development of CTE.

1.2

Chronic Traumatic Encephalopathy

History of Chronic Traumatic Encephalopathy
In 1928, an initial description of what is now known to be CTE was first described by Dr.
Martland as he analyzed the brain pathology and behaviours of boxers known to be
“punch drunk” who had developed both mild and severe symptoms (Martland, 1928). He
proposed that the development of the “punch drunk” syndrome was the result of multiple
injuries to the head (Martland, 1928). In 1934, Dr. Parker expanded upon the work of Dr.
Martland and referred to the syndrome as “traumatic encephalopathy” (Parker, 1934).
Dr. Parker confirmed that repeated injuries to the head sustained during the sporting
careers of boxers leads to the development of numerous symptoms, which he referred to
as a ‘medley’ of symptoms (Parker, 1934). Later, in 1937, another scientist named
Millspaugh observed similar symptoms and behaviours as Martland, mostly in boxers,
and used a different term, “dementia pugilistica” (Baugh et al., 2012). Many other
scientists and researchers over time have looked into this phenomenon and many names
were put forward (Stein et al., 2014). It was during the 1940s that the term “Chronic
Traumatic Encephalopathy” (CTE) was coined, and it is now widely used and accepted
(Montenigro et al., 2015). Since then, the study of CTE has advanced and the natural
progression of CTE has been characterized (McKee et al., 2013).

11
Risk Factors for Chronic Traumatic Encephalopathy
Both environmental and genetic risk factors, and the interaction between these risk
factors, play a role in the development of CTE (Gavett et al., 2010). The most obvious
environmental risk factor for the development of CTE is the exposure to rmTBIs (Gavett
et al., 2010, 2011; McKee et al., 2009). As mentioned previously, individuals who
participate in contact sports, are enrolled in the military, suffer from domestic abuse, or
have any instance where exposure to repeated concussive or sub-concussive impacts is
increased, have a greater risk of developing CTE (Baugh et al., 2012). Individuals who
experience frequent falls, vehicular accidents, or have epilepsy are also populations at
risk for the development of CTE (Gavett et al., 2010).
Genetic background also plays a role in the recovery from TBI and may explain some of
the variability seen in the recovery process (McAllister, 2010). Candidate genes and their
respective alleles, as well as various epigenetic factors acting on these genes, can act
alone or interact and therefore influence the outcome(s) post-injury (McAllister, 2010).
There are several known genetic risk factors associated with a poorer outcome post-injury
(J. Hay et al., 2016). Individuals with the APOE Ɛ4 allele and/or the longer microsatellite
polymorphism repeat located in the promoter in the neprilysin gene (NEP) are subject to
a greater risk for the development of amyloid beta (Aβ) plaques, and neurological
impairment post-TBI (J. Hay et al., 2016).

Polymorphisms in TP53, angiotensin-

converting enzyme (ACE), and calcium channel subunit gene (CACNA1A), are also
associated with a poorer outcome post-TBI (McAllister, 2010). The involvement of
many genes in the molecular cascades activated by secondary injury mechanisms is
believed to explain why so many genes may influence the level of risk for developing
neurodegenerative disease following TBI (McAllister, 2010).
Progression of Chronic Traumatic Encephalopathy
In 2013, McKee and colleagues set out to characterize the progression and spectrum of
the neuropathological changes associated with CTE (McKee et al., 2013). The results
demonstrate that the brains of concussed subjects analyzed could be sorted into one of
four stages with a distinct pattern of pathological protein and other microscopic changes.
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Stage I is the mildest of the stages of CTE progression. Brains classified as stage I CTE
show little ventricular enlargement with focal perivascular pathological tau protein
located in the depths of cortical sulci. Brains classified as stage II (mild CTE) show
ventricular enlargement, increases in pathological tau protein that penetrate the
superficial layers of the cortex, and small amounts of pathological tau in areas such as the
hippocampus, entorhinal cortex, and thalamus. Brains classified as stage III (moderate
CTE) show areas of brain atrophy, axonal loss in subcortical white matter, and increased
pathological tau spread throughout the cortices, hippocampus, entorhinal cortex and
amygdala. The final stage of CTE, Stage IV, is the most severe stage. This stage
includes significant brain atrophy in several brain areas, decreased overall brain weight,
significant ventricular enlargement, significant neuronal death and widely distributed
pathological tau protein. The complete characterization of the progression of CTE can be
found in the paper of McKee et al. (2013), with more information found in the work of
Stein and fellow colleagues (Stein et al., 2014). Overall, the pathology of CTE increases
as the stages progress from Stage I (very mild) to Stage IV (severe). Although CTE can
be present alongside other neurodegenerative diseases and have other pathological
proteins/processes present, CTE is characterized as a tauopathy due to the fact that the
main pathological hallmark is the deposition of pathological phopho-tau aggregates.

1.3

Tau

The Microtubule-Associated Protein Tau (MAPT)
Tau proteins are members of the microtubule-associated protein (MAP) family (Binder et
al., 1985; Brandt et al., 2005). The main function of tau is to help stabilize, bind, and
regulate microtubule dynamics in the axons of neurons (Arendt et al., 2016). However,
there are many other functions of tau within cells, such as interacting with other cellular
components, like the mitochondria and the plasma membrane, and potentially playing a
role in various signaling processes (Kolarova et al., 2012).
Tau proteins are expressed both in the peripheral nervous system and in the central
nervous system (Arendt et al., 2016), with trace amounts of tau mRNA in several
peripheral tissues (Buée et al., 2000). Within the central nervous system, tau proteins are
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expressed predominantly in neurons (Kolarova et al., 2012). Tau can also be found both
within oligodendrocytes (Arendt et al., 2016) as well as in astrocytes (Arena et al., 2020).
In healthy neuronal cells tau is localized in the axonal compartment, where it’s primary
function is to interact with microtubules (M Goedert & Jakes, 1990). With regard to
human tau proteins, the single gene responsible for the production of all of the tau family
members is located on chromosome 17, position 17q21 (Kolarova et al., 2012). There are
a total of 16 exons contained within this gene, of those, 11 are involved in alternative
splicing (Brandt et al., 2005; M Goedert et al., 1988). Three of the exons are not
transcribed in the brain at all, specifically, exons 4A, 6 and 8 (Park et al., 2016). The
alternative splicing generates six unique tau isoforms that differ with respect to the
number of binding domain repeats at the C-terminal end and either the presence or
absence of two N-terminal amino acid inserts (Arendt et al., 2016). Specifically, the
regions subjected to alternative splicing, that create the unique isoforms in the brain, are
encoded by exons 2, 3, and 10 (M Goedert et al., 1989; Park et al., 2016). Exons 2 and 3
can be spliced so that neither of them, exon 2, or both exon 2 and 3 can be included in the
structure of the isoforms, resulting in a 0N, 1N, or 2N isoform (Arendt et al., 2016; Park
et al., 2016). The alternative splicing of exon 10 results in either the exclusion of this
exon, 3R tau isoforms, or the inclusion of this exon, resulting in 4R tau isoforms (Brandt
et al., 2005). As a result, of these combined alternative splicing’s, six tau isoforms are
generated and are referred to as 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R (Kolarova
et al., 2012). It is important to note that the previously described tau isoforms apply to
the tau isoforms located in the central nervous system, as the peripheral nervous system
has an additional tau isoform, referred to as “big tau” (Brandt et al., 2005; M Goedert et
al., 1992).
The Structure and Developmental Expression of Tau
Tau is a natively unfolded protein with little secondary structure (Arendt et al., 2016;
Kolarova et al., 2012). However, the differences between the various tau isoforms dictate
the functional outcome of each of the proteins, and therefore influence their interactions
with microtubules, especially during development (Kolarova et al., 2012).

During

development, the tau isoforms are differentially regulated and expressed (Kosik et al.,
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1989). In the fetal brain, only 3R isoforms are expressed, whereas in the adult human
brain, both 3R and 4R isoforms are expressed equally at a ratio of approximately 1:1 (M
Goedert & Jakes, 1990; Hanes et al., 2009). It has been demonstrated that the 4R isoform
is capable of binding microtubules more efficiently than their 3R counterparts (M
Goedert & Jakes, 1990). This seems to reflect the change in plasticity within the brain as
it ages, as 3R tau’s weak binding to microtubules will allow for greater neuroplasticity
during neuronal development while the strong microtubule binding of 4R tau will
decrease neuroplasticity by enhancing microtubule stability (Arendt et al., 2016).
Post-Translational Modifications of Tau
Tau proteins are not only regulated by alternative splicing throughout development, but
also by various post-translational modifications. These modifications influence tau’s
ability to bind and stabilize microtubules (Sergeant et al., 2005). Tau can be modified
through the process of O-glycosylation, glycation, ubiquitination, SUMOylation,
nitration, methylation, acetylation, truncation, and more, all of which affect tau’s ability
to function and potentially become pathogenic (Arendt et al., 2016). The most studied
and well-known modification of tau is its phosphorylation at regulatory sites. Tau itself is
considered a phosphoprotein (Trinczek et al., 1995), as there are approximately 80 sites
available for potential phosphorylation on the longest tau isoform (Sergeant et al., 2005).
Pathological phosphorylation of tau leads to the deposition of tau aggregates and disease.
Tau and Tauopathies
Tauopathies are a group of heterogeneous neurodegenerative diseases characterized by
filamentous tau aggregates consisting of hyperphosphorylated tau proteins (Kovacs,
2018; V. M.-Y. Lee et al., 2001). Tauopathies may be classified based on the unique
composition of their tau aggregates (Sergeant et al., 2005). Tauopathies can be further
subdivided into either sporadic or familial tauopathies, in which sporadic tauopathies
arise spontaneously and familial tauopathies arise due to inherited mutations (Arendt et
al., 2016). Tauopathies may also be classified as either primary or secondary, depending
on how significant the tau pathology is, and the severity of other coincident pathological
features (Kovacs, 2018). Each tauopathy is unique, as the distribution of tau, isoforms
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present, isoform ratio balance, and presence/absence of other pathological features is
specific to each respective disease (Arendt et al., 2016; Sergeant et al., 2005).
Familial Tauopathies
Over 30 genetic mutations have been implicated in the development of familial
tauopathies (Engel et al., 2006; Michel Goedert & Jakes, 2005). Missense, deletion, and
silent mutations involving the exons of the tau gene can influence the outcomes of
alternative splicing, as can various mutations in the intron sequences (Niblock & Gallo,
2012). When the regulation of alternative splicing becomes altered, the production of 3R
and 4R tau isoforms becomes unbalanced, affecting the normal physiological isoform
ratio (Niblock & Gallo, 2012). Besides mutations to the introns, exons, or both the
introns and exons, there can also be genetic alterations involving the entire sequence of
the tau gene. The genetic inversion of the DNA region containing the tau MAPT gene
results in the production of two haplotypes, H1 and H2, with the H1 haplotype having
several sub-haplotypes, some of which are associated with the development of
tauopathies (Niblock & Gallo, 2012; Sánchez-Juan et al., 2019).
Sporadic Tauopathies
Typically, sporadic tauopathies originate in a vulnerable area of the brain and
subsequently the pathological tau aggregates spread throughout the rest of the brain
through the neuronal pathways connecting them (Sergeant et al., 2005). When the ratios
of 3R:4R isoforms become unbalanced or the modifications influencing tau’s activity
become dysregulated, or external triggers, such as substance abuse or brain injuries,
occur, sporadic tauopathies may emerge (Arendt et al., 2016; Irwin et al., 2013).
Tau as a Prion Protein
A proposed mechanism for the propagation of pathological tau throughout the brain is via
a prion-like mechanism. This mechanism involves the corruption of native proteins into
pathological proteins and aggregates using a template-dependent manner from
pathological tau (Kumar & Udgaonkar, 2018). The forms of pathological tau, in this
case, are referred to as “strains” and each strain has a distinct fibrillar structure (Sanders
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et al., 2014). The characteristics of each strain determines the characteristics of the
disease that manifests. These strains of pathological tau are stable and are able to
propagate from cell-to-cell through synapses (Mudher et al., 2017). This could explain
how tau is able to spread from vulnerable brain regions to connecting brain areas.
Imbalance of Post-translational Phosphorylation of Tau
There have been several studies that have investigated various post-translational
modifications of tau and how these modifications play into aggregate formation and/or
disease progression (Arendt et al., 2016; Morris et al., 2015). Of particular interest is the
post-translational phosphorylation of tau. As mentioned above, tau is known to be a
phosphoprotein in which the level of phosphorylation naturally influences and regulates
tau function (Buée et al., 2000; Trinczek et al., 1995). However, diseases may arise when
tau becomes pathologically hyperphosphorylated (Kolarova et al., 2012). It has been
proposed that an imbalance in the activities and regulations of protein kinases and
phosphatases results in the hyperphosphorylation of tau, either through an increase in
kinase activity or a decrease in phosphatase activity (Buée et al., 2000).

1.4

Glycogen Synthase Kinase 3

Overview
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed proline-directed
serine/threonine kinase that is constitutively active (Beurel et al., 2015; Hooper et al.,
2008). It consists of two important functional domains: a primed substrate binding
domain and a kinase domain (Beurel et al., 2015). Initially discovered in the 1970s for its
role in the phosphorylation and regulation of glycogen synthase, GSK3 has since been
implicated in many other cellular and signaling pathways (Cohen & Goedert, 2004).
GSK3 is involved in glycogen metabolism, gene transcription, apoptosis, inflammation,
and microtubule stability, just to name a few cellular processes (Cohen & Goedert, 2004;
Hooper et al., 2008). There are two unique aspects to GSK3 activity: 1) GSK3 is
constitutively active and 2) GSK3 may phosphorylate both primed and un-primed
substrates (Beurel et al., 2015; Hooper et al., 2008). The “priming” of the substrates
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involves the phosphorylation of a site approximately 4 residues to the C-terminal side of
the target site, which allows the substrate to bind to the GSK3 primed substrate binding
domain (Beurel et al., 2015).

GSK3 is regulated by a number of kinases and

phosphatases and the breakdown of these regulations has been implicated in the increased
risk of disease (Hooper et al., 2008).
Regulation of Glycogen Synthase Kinase 3
There are many post-translational regulatory mechanisms that keep the activity of GSK3
in check. Post-translational modifications, substrate priming, association with protein
complexes, and regulation of expression and degradation are all mechanisms that are
capable of regulating GSK3 (Beurel et al., 2015). Post-translational acetylation of GSK3
can influence whether GSK3 activity is increased or decreased. When acetylated, the
activity of GSK3 proteins is suppressed, however, when the proteins become
deacetylated, the levels of activity increase (Monteserin-Garcia et al., 2013). Much more
work needs to be done in order to tease apart the effect that other non-phosphorylation
dependent post-translation modifications have on GSK3 activity (Beurel et al., 2015).
Substrate priming is another method of controlling the levels of activity of GSK3. This
method is more complex than mere post-translational modifications, as not only does the
substrate have to be pre-phosphorylated at the correct site, thus being primed for GSK3
proteins, but activated GSK3 proteins must be in the vicinity of the primed substrate
(Beurel et al., 2015). The priming of the substrate requires that other signaling pathways
be active and phosphorylating the desired substrate at approximately 4 residues Cterminal to the target motif (Beurel et al., 2015). One way to directly influence the
activities of GSK3 phosphorylation is to incorporate GSK3 into a number of different
protein complexes, depending on the desired substrates and outcomes. For example, one
of the most well known protein complexes involving GSK3 is the destruction complex of
the Wnt signalling pathway (Kim et al., 2009). GSK3 forms a destruction complex with
various other proteins in order to phosphorylate and target β-catenin for degradation (Kim
et al., 2009). In addition to these methods of regulating GSK3 activity, GSK can also be
regulated by its cellular sequestration to the mitochondria, the nucleus or the cytosol, of
the cell (Beurel et al., 2015). In the next section I will discuss the regulation of GSK3
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activity by phosphorylation of GSK3’s main regulatory sites that vary depending on the
isoform/paralog of interest (Beurel et al., 2015).
Isoforms of Glycogen Synthase Kinase 3
There are two major paralogs, sometimes referred to as isoforms, of GSK3, one is
glycogen synthase kinase 3-alpha (GSK3α) and the other is glycogen synthase kinase 3beta (GSK3β) which are each produced from their respective genes (Beurel et al., 2015;
Soutar et al., 2010). There is a final form of GSK3, which is the product of a splice
variant of GSK3β, a protein known as GSK3β2. This splice variant is known to be
enriched within the neurons of the central nervous system, in particular the brain (Soutar
et al., 2010). The activity of GSK3α and GSK3β can be regulated by several different
mechanisms, however, the phosphorylation of two specific residues, a tyrosine residue
and a serine residue, are of the greatest importance. When tyrosine 279 (Tyr279) is
phosphorylated (pTyr279) in GSK3α the activity of GSK3α is increased and when serine
21 (Ser21) is phosphorylated (pSer21) the activity is decreased (Fang et al., 2000;
Medina & Wandosell, 2011). Similarly, if tyrosine 216 (Tyr216) on GSK3β is
phosphorylated (pTyr216) the activity is increased, and when the serine 9 (Ser9) residue
is phosphorylated (pSer9) the activity is decreased (Fang et al., 2000; Krishnankutty et
al., 2017). Although the isoforms are similar, they have distinct substrate preferences
(Soutar et al., 2010). GSK3β has the most predicted substrates than any other kinase,
with over 500 predicted substrates (Beurel et al., 2015; Linding et al., 2007). One of the
substrates of interest, tau (the microtubule-associated protein), has been shown to be a
substrate for GSK3β, and in the case of disease development, the hyperphosphorylation
of this protein by GSK3β has been associated with increased pathological outcomes
(Avila et al., 2012).

1.5

Glycogen Synthase Kinase 3-beta and Tau

Phosphorylation of Tau by Glycogen Synthase Kinase 3-beta
Many studies have investigated the relationship of tau, its phosphorylation by GSK3β,
and the risk of disease. In tauopathies, tau is abnormally phosphorylated, above the
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physiological levels resulting in the production of toxic conformations which form
aggregates leading to neurofibrillary tangle (NFTs) development (Hanger et al., 2009).
GSK3β is capable of phosphorylating tau at both primed and un-primed sites (Cho &
Johnson, 2003), therefore creating more opportunity for increased tau phosphorylation.
GSK3β displays more activity towards tau and is known to co-localize with
hyperphosphorylated tau proteins (Tsujio et al., 2000). The overall levels of GSK3 are
also increased within Alzheimer’s diseased brains by at least 50% (Tsujio et al., 2000).
One study investigated the activities of kinases acting on recombinant tau using
nanoelectrospray mass spectrometry and demonstrated that GSK3β is capable of
phosphorylating tau at several known sites contained within paired helical filament (PHF)
tau aggregates (Reynolds et al., 2000). A desirable goal might be to disrupt or halt the
process of tau phosphorylation entirely by administering inhibitors to block kinase
activity (Hanger et al., 2009).
Inhibitors Prevent Kinase Activity
The foregoing discussion of GSK3’s role in tau phosphorylation and the role of
pathological tau phosphorylation in disease suggests that GSK3 inhibition might be an
attractive strategy for the treatment or prevention of tauopathies. GSK3β inhibitors can
be classified into two main categories, one being ATP competitive inhibitors, and the
other being non-ATP competitive inhibitors (Eldar-Finkelman et al., 2010). Since ATP
binding sites are very highly conserved domains in kinases, it is ideal to use non-ATP
competitive inhibitors in order to increase the specificity for GSK3 proteins and
minimizing any off-target effects (Eldar-Finkelman et al., 2010). The most appealing
non-ATP competitive inhibitors for targeting GSK3 proteins are ones that compete with
GSK3 substrates for binding, termed substrate competitive inhibitors (Eldar-Finkelman et
al., 2010).

However, the production of GSK3 inhibitors includes many types of

chemicals with many different modes of action. Some of the main groups of inhibitors
are the maleimides derivatives, aminopyrimidines, the amino thiazoles, and the
thiadiazolidinones (TDZD) (Cohen & Goedert, 2004; Eldar-Finkelman et al., 2010). One
group investigating the effects of GSK3 inhibition on a double transgenic mouse line that
develops AD-like pathology found that upon inhibition of GSK3β with NP12 (a TDZD,
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non-ATP competitive), there were decreased levels of phosphorylated tau, and decreased
cell death (Serenó et al., 2009) among other molecular, cellular, and cognitive benefits.
Another study investigated the mechanism of GSK3β activation, through the
phosphorylation of tau at Thr175, that leads to the subsequent phosphorylation of tau at
Thr231, fibril formation, and cell death (Moszczynski et al., 2015). Four inhibitors of
GSK3β were used; lithium chloride, AR-A014418, Tideglusib (aka NP12), and TWS119; all of which successfully prevented pathological fibril formation and cell death
(Moszczynski et al., 2015).

1.6

Models of Traumatic Brain Injury

Invertebrate Models
Caenorhabditis elegans (C. elegans) are nematodes that are considered to be a valued
model organism (Hill et al., 2000). These metazoans have had their entire genome
completely sequenced in the 1990s, therefore making genetic studies possible and easily
accessible (Hill et al., 2000). One group has studied the effects of surface acoustic waves
(SAW) in producing similar pathologies in C. elegans comparable to blast induced TBIs
seen in military and civilians affected by war (Miansari et al., 2019). This group saw that
there was decreased mobility and short-term memory impairment upon SAW injury.
Another model organism are the flies known as Drosophila melanogaster (Adams et al.,
2000). One team of researchers set out to develop a closed head model of TBI using
Drosophila melanogaster and discovered that these flies face similar post-TBI injuries
compared with humans that have suffered from TBI (Katzenberger et al., 2013). These
models offer the benefits of being cheap to maintain, time efficient (with short lifespans),
and significant knowledge of their genetic backgrounds has been developed
(Katzenberger et al., 2013; Miansari et al., 2019). Although these models of TBI have
useful insights into pathological mechanisms and molecular and cellular cascades that are
initiated post-injury, there are several drawbacks that must be considered. For example,
there are limited tests available to evaluate complex behaviours in these organisms (Shah
et al., 2019).

Second, these model organisms are too small to administer potential

therapeutic drugs and observe the effects on behavioural outputs, thereby limiting their
clinical relevance (Shah et al., 2019).
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Vertebrate Models
The effects of TBIs have been investigated using different methods of delivering injuries
(fluid percussion injury, FPI; controlled cortical impact injury, CCI; weight drop models,
and blast injuries) and using different animal models (cats, dogs, sheep, rabbits, pigs,
ferrets, and monkeys) (Xiong et al., 2013). Although the possible combinations may offer
a lot of insight into the mechanisms behind the pathology of TBIs and disease
development, there are some drawbacks to consider in using large animal models. For
instance, it is difficult to find suitable equipment in order to deliver consistent, precise
injuries to larger animals. It is also difficult to find enough space to house the animals
(Cernak, 2005). Larger animals also mean larger costs for proper housing, care and
enrichment.

Large animal experiments in TBI may also raise more ethical issues

(Cernak, 2005).
Rodent Models
There is always the struggle of taking results from scientific studies involving animal
models and then applying them to human beings (Risling et al., 2019).

However,

technological advancements have allowed the development of genetic tools that have
been applied to rodents in order to create ideal transgenic models with greater clinical
relevance to human disease. Rodents are also ideal models due to the fact that they are
small, and therefore space efficient, and also able to quickly increase their numbers
through reproduction to repeatedly run morphological, cellular, biochemical, and
behavioural analyses (Cernak, 2005). Several transgenic mouse models have already
been created in order to tease apart the interactions between rmTBI, GSK3β, and tau.
The downside of the previous transgenic models is that they fail to express all tau
isoforms in the same proportions as found in humans, a ratio of 1:1 for 3R:4R
respectively (Hanes et al, 2009). As previously mentioned, the balance of the 3R:4R
ratio of tau isoforms is critical for models of tauopathies, as a disruption to this balance
can result in tau pathology, without the addition of other factors, and ultimately CTE
(Hanes et al, 2009; Sergeant, Delacourte, and Buée, 2005). A rat model of hypertension
was shown to have different ratios of 3R:4R tau isoforms depending on the brain area of
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interest (Cortex 1:9, Hippocampus 1:7, and Brainstem 1:6) (Hanes et al, 2009) compared
to the htau mouse model with an isoform imbalance leaning towards more 3R tau than 4R
tau (Andorfer et al., 2003). However, a group of scientists have created a brand new,
improved mouse model of tauopathy, the MAPT knock-in mouse (MAPT KI mice) (Saito
et al, 2019). Overall, the new mouse strain was created by replacing the entire murine
Mapt genetic sequence with the human MAPT sequence (exons 1-14) through
homologous recombination. The targeting construct, including the neomycin-resistant
gene (neo) flanked with loxP sites, was injected into ES-R1 cells, and once selected the
positive clones were injected into C57BL/6 blastocysts. The resulting chimeric mice
were then crossbred with EIIa CRE mice in order to get rid of the neo gene, and the mice
were then backcrossed with C57BL/6 mice for 5 generations. This mouse strain was
developed in order to express all six human tau isoforms without any expression of
murine tau, resulting in a tau isoform ratio of approximately 1:0.66 3R:4R (Saito et al,
2019), which is much closer to that seen in humans. Therefore, this new mouse strain
serves as an ideal model for studying the mechanisms of tau phosphorylation in
tauopathies, and potential avenues for therapeutic targets. In order to ensure that this
study is able to capture a more realistic outcome of tau pathology in humans, and
therefore be more clinically relevant, the MAPT KI mouse strain (Saito et al, 2019) will
be used.

1.7

Rationale, Goals and Aims for Thesis

Rationale
Repetitive mild traumatic brain injury (rmTBI) is known to be a risk factor for the
development of neurodegenerative diseases such as Chronic Traumatic Encephalopathy
(CTE) (Ojo et al., 2013). It is also known to influence the activity of glycogen synthase
kinase 3-beta (GSK3β), a kinase with many functions, one of which is to phosphorylate
tau (Moszczynski et al, 2018).

Previous studies have shown that the activation of

GSK3β, as a result of brain injury, leads to many detrimental cascades including
abnormal increases in tau phosphorylation (Moszczynski et al, 2018). These increases in
tau phosphorylation are above the natural levels found within cells, and lead to the
pathology seen in diseased states. Hyperphosphorylated tau is prone to misfolding,
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aggregation, fibril formation, and tangle formation, leading to neuron death and other
pathologies (Polydoro et al., 2009). The need for a more clinically relevant model of
rmTBI is an important milestone that must be reached. By using the newly generated
humanized MAPT KI mice in this model of closed skull/closed skin rmTBI, we are taking
one step further towards better understanding the relationships between all of these
phenomena.
Goals and Aims for this Thesis
The overarching goal of this thesis is to validate and characterize a closed skull, closed
skin model of rmTBI using the MAPT KI mouse. This work will set the stage for future
studies to evaluate the pathophysiology of rmTBI and to test possible therapeutic
strategies.
Goal
To develop and evaluate a mouse model of concussion in order to study the relationship
between rmTBI, GSK3β activity, tau phosphorylation, and the development of cognitive
deficits in a transgenic mouse line expressing solely human tau.
Aims
1. To investigate the time course of GSK3β activity in different regions of the brain
in wildtype rmTBI mice.
2. To characterize the cellular and molecular pathology in rmTBI MAPT KI mice.
3. To characterize the behavioural outcomes of rmTBI in the MAPT KI mice, using
the Elevated Plus Maze (to test for anxiety/anxiety-like behaviours) and the
Morris Water Maze (to test for spatial learning/memory).
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Chapter 2
2

Materials and Methods

2.1

Animals

All experiments were approved by the Western University Animal Care Committee
which adheres to the Canadian Use of Experimental Animal Guidelines. Male and female
C57BL/6 mice were purchased from Charles River (Quebec, Canada). Male and female
MAPT KI mice, obtained from Dr. Hashimoto et al. (2019), were bred in house. All mice
were kept on a 12 hour light : 12 hour dark cycle, and had free access to food and water.
All experiments were performed during the light cycle. Mice were housed together, with
a maximum of four mice per cage.

2.2

Repetitive Mild Traumatic Brain Injury Procedure

To model concussion in mice in a clinically relevant way, we performed an injury in
which the skin and skull were kept intact. Mice were randomly assigned to receive either
a repetitive mild traumatic brain injury (rmTBI), a sham procedure, or to act as naïve
controls. Before any injuries were delivered, the controlled cortical impact (CCI) device
(TBI 0310, Precision Systems and Instrumentation) was calibrated to the desired
experimental parameters. Mice were then anesthetized using 3% isoflurane for induction
and maintained on 2% isoflurane using a nose-cone. The hair on the scalp was shaved
before the concussion or sham procedure and the mice, along with the nose-cone for
anesthetic administration, were transferred directly under the CCI device (TBI 0310,
Precision Systems and Instrumentation) that was used to deliver a mild traumatic brain
injury. The tip of the impactor was aligned with the approximate center of bregma. The
impact was then delivered with a custom-made silicone impactor tip of 4 mm diameter, at
a programmed velocity of 3.5 m/s, at 1.0 mm depth, and with 500 msec dwell time. Mice
were subjected to 5 concussions with a 24 hour inter-injury interval time in order to
achieve an rmTBI model. Sham mice underwent 5 minutes of isoflurane anesthesia each
day for 5 days with a 24 hour interval between sham procedures. Naïve mice were not
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manipulated. Mice were sacrificed at various time points after the final concussion or
sham procedure.

2.3

Silver Staining

The silver staining procedure followed was provided by the manufacturer of the FD
NeurosilverTM Kit II (FD NeuroTechnologies, Ellicott City, MD). After the coronal brain
sections (50 m thickness) were stained, they were then promptly mounted on VWR
microslides (25x75 mm, 1.0 mm thick) and allowed to air dry in the fume hood. Once
dry, the slides were rinsed in a xylene solution three times, for three minutes each time,
and then sealed by a cover-slip. Two slides per animal, containing approximately five
sections per slide, were selected for analysis. In total, approximately 3-4 sections per
animal were visually inspected for positive silver staining. Slides were imaged using an
Olympus BX50 brightfield microscope. Images were taken along the corpus callosum.
Images were taken for all animals in each experimental group (n’s specified in the
experimental timelines below).

2.4

Tissue Preparation for Western Blots

The mice that were assigned to be used for Western blot analyses were transcardically
perfused using a chilled saline solution. Once perfused, brains were extracted and the
regions of interest, the cortex and the hippocampus, were dissected free of the rest of the
brain.

The cortex and hippocampus samples were sonicated in RIPA lysis buffer

supplemented with Halt protease and phosphatase inhibitor cocktail (Life Technologies;
#78440) at a dilution of 1:100. The sonicated mixture was then centrifuged at 6000 rpm
for 20 minutes at 4 °C. Afterwards, the supernatants were aliquoted into separate tubes
for storage at -80 °C. Protein concentrations were determined by a Bradford protein
assay for each sample in order to load an equal concentration of protein to each lane in
the Western blots (10 g/lane).

2.5

Glycogen Synthase Kinase 3 Western Blots

Mice were sacrificed at various time points after the last impact/sham injury was
delivered (Refer to Figure 1 and Table 2). A group of naïve mice were also sacrificed to
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provide an additional control. A standard Western blot protocol was followed (Abcam),
in which a 10% acrylamide gel was used as the resolving gel, with a 4% acrylamide
stacking gel. The protein gels ran for approximately one hour at 80 V until samples
entered the bottom resolving, gel, at which time the voltage was increased to 100 V.
Western blots were then transferred from the gel to Millipore Immobilon-FL PVDF
membranes for approximately 1.5-2 hours at 110 V. Membranes were then dried,
trimmed, and stored at 4 °C overnight. Membranes were then blocked in Intercept
Blocking Buffer (TBS) from LI-COR for approximately an hour, and then incubated in a
primary antibody overnight. To detect β-actin we used either a rabbit anti-β-actin from
LI-COR Biosciences (#926-42210; Waller et al., 2017) or a mouse anti-β-actin from LICOR (#926-42212; Almanzar et al., 2016), each at a dilution of 1:5000, depending on the
primary antibody used to detect the GSK3β proteins. To detect total GSK3 (GSK3 TOT)
we used a mouse anti-GSK3β from BD Transduction Laboratories at a dilution of 1:5000
as the primary antibody (Lucas et al., 2001). To detect GSK3β phosphorylated on
tyrosine 216 (pTyr216) we used a mouse anti-GSK3β pTyr216 from BD Transduction
Laboratories at a dilution of 1:1000 as the primary antibody (Bhat et al., 2000). To detect
GSK3β phosphorylated on Serine 9 (pSer9) we used a rabbit anti-GSK3β pSer9 from
Biorad at a dilution of 1:1000 as the primary antibody (Stambolic & Woodgett, 1994).
Membranes were then washed in TBST three times, ten minutes each time, and incubated
in secondary antibody (either a donkey anti-mouse (680; red) or a donkey anti-rabbit
(800; green) antibody (LI-COR Bioscience) as appropriate) for an hour. Afterwards,
membranes were washed in TBST three times (ten minutes each time), and TBS for ten
minutes. Membranes were imaged using the Odyssey Imaging System (LI-COR
Bioscience) imaging software. The relative optical densities of the proteins of interest
were quantified using ImageStudio Plus software.

Densitometric values for target

proteins (GSK3 TOT, pTyr216, pSer9) were normalized to the densitometric values for
β-actin, and then compared to the values obtained for naïve animal samples that were
present on each blot. Each set of animals, shams and injured, were run on the same set of
gels. Each set of gels were produced with alternating orders of samples to prevent
position bias within the gels, which were referred to as “Formats”. Each gel that was
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produced had the same naïve sample to act as a control across all blots to ensure that
results could be compared across all gels, and therefore across all time points.

2.6

Tissue Preparation for Immunohistochemistry

MAPT KI mice were sacrificed at various time points after the last impact or sham
procedure (Refer to Figure 2, Table 3, and Table 4). A group of naïve mice were also
sacrificed to provide an additional control. Mice were perfused with saline, followed by
4% paraformaldehyde. Brains were dissected and post-fixed in 4% paraformaldehyde
overnight at 4 °C and then transferred to 20% sucrose solution the next day and left in at
4 °C overnight. Brains were then patted dry, transferred into plastic brain moulds,
immersed in OCT, and then stored in the -80 °C freezer.
The fixed brains were sectioned in the coronal plane on a cryostat. For silver staining
floating sections at 50 µm thickness were collected. For immunohistochemistry 18 µm
thick sections were thaw-mounted directly onto slides. Thirty slide sections and ten
floating sections were collected in an alternating fashion until the desired amount of
sections were collected.

Floating sections were stored in six-welled plates in 8%

sucrose/0.5% sodium azide solution and later transferred to 4% paraformaldehyde once
all of the brains were processed. The floating sections were then processed according to
the silver staining protocol, mounted on slides, and allowed to dry overnight in the fume
hood before being sealed by a cover-slip (see above for more details). Slide sections
were stored in a labelled box in the -80 °C freezer until they were used for
immunohistochemical staining.

2.7

Immunohistochemistry

AT8, GFAP and IBA1
Slides were removed from the -80 °C in order to thaw to room temperature for 30
minutes. Once thawed, slides were washed in 1xPBS (Phosphate Buffered Saline) twice
for five minutes each. Slides were then covered in blocking medium (1xPBS, Goat
Serum, Triton-X-100) for approximately 2 hours and left at room temperature. The
primary antibodies, which were diluted in blocking medium, were applied. To detect
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pathologically phosphorylated tau (phospho-tau (Ser202, Thr205) monoclonal mouse
AT8 (1:100 dilution) from Invitrogen was used (Y. Zhang et al., 2019). To detect glial
fibrillary acidic protein (GFAP) a marker of activated astrocytes a mouse anti-GFAP
(1:500 dilution) from Sigma was used (Lazarus et al., 2015). To detect Iba1, a marker of
microglia, a rabbit anti-Iba1 (1:1000 dilution) from Novus Biologicals was used (Schultz
et al., 2018). The slides were then “cover-slipped” with a section of parafilm and
incubated at 4 °C. The following day, the slides were washed in 1xPBS, three times, for
30 minutes each. The slides were then incubated in the appropriate secondary antibody
(either donkey anti-mouse 595 (Life Technologies) or donkey anti-mouse 488
(Invitrogen) or donkey anti-rabbit 594 (Invitrogen)) for 45 minutes at a 1:500
concentration while “cover-slipped” with a new section of parafilm. After the incubation,
the slides were washed in 1xPBS three times for 30 minutes each time. The slides were
briefly washed in double distilled water before applying VectaShield Hardset Antifade
Mounting Medium with DAPI (Vector Laboratories, Inc.) and stored at 4 °C.
Image Analyses
Two slides, containing approximately five sections per slide, were made for each animal
in each treatment group. Out of those sections, 2-3 sections were visually analyzed for
positive staining. Slides were imaged using an Olympus BX50 brightfield microscope.
Images of the prefrontal cortex area were visually analyzed for positive AT8 staining.
Images of the corpus callosum were visually analyzed for positive GFAP/Iba1 staining.
All images were taken at 40x magnification, and images were taken of all animals in each
experimental group (n’s specified in experimental timelines and in related figures). Dr.
Kathy Xu of the Brown Lab generously donated representative images of both sham and
injured C57BL/6 male mice for comparison against the MAPT KI mice.

2.8

Elevated Plus Maze Test

Behaviours in both male and female MAPT KI mice were evaluated by the Elevated Plus
Maze (EPM) test in order to assess anxiety/anxiety-like behaviours (Broussard et al.,
2018). Eight and a half weeks after the last concussion injury or sham procedure mice
were placed in the centre of the maze platform facing one of the closed arms and allowed
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to freely explore for a total of five minutes. Each mouse had one trial and after the trial
was concluded the maze was sanitized with 70% ethanol. The behaviour of each mouse
in the maze was video recorded and then analyzed using ANY-Maze (Stoelting Co.
Wood Dale, IL) for the time spent in each of the 3 defined areas (closed arms, open arms,
centre) as well as the speed, and distance travelled.

2.9

Morris Water Maze Test

During the ninth week after the last concussion injury or sham procedure both male and
female MAPT KI mice underwent evaluation of spatial learning and memory using the
Morris Water Maze (MWM) (Mannix et al., 2014; Xu et al., 2021). Training on the
MWM occurred on four consecutive days (4 trials per training day per mouse). Each day
of training had four trails that each had a different starting position corresponding to each
of the four quadrants in the maze. The order of the starting positions was changed
randomly on each training day to prevent repetition. Mice were placed in the water,
facing the wall of the maze and allowed to freely swim/explore for a minute per trial. The
goal of the maze is to locate the hidden transparent platform, placed 1 cm under the
water, located in quadrant 4. Successful trials concluded when the mouse located the
hidden platform and was removed from the maze. Unsuccessful trials, trials in which the
mouse was unable to find/locate the hidden platform, concluded with the mouse being
placed on the hidden platform for approximately 20 seconds and then being removed
from the maze. After the four days of training was completed, a Probe Trial was
conducted on the fifth day in which the hidden platform was removed from the pool and
the mice were allowed to freely swim around the pool for one minute. One week after the
first probe test, mice underwent a retention trial, again with the platform removed, and
were allowed to swim freely for one minute. For both the probe and retention trials mice
were placed in quadrant 2, across from the target quadrant, and were only tested for that
one trial. The testing information was recorded with a video camera placed above the
pool area, and analysis was conducted by the ANY-Maze software (Stoelting Co. Wood
Dale, IL).
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2.10 Experiment 1: Pilot Study
Five C57BL/6 mice were used for this study, 2 naïve mice and 3 rmTBI mice (Table 1).
A depth of 1.0 mm was used during the pilot study in order to determine if this would be
sufficient enough to cause the desired effect of a mild traumatic brain injury, without
fracturing the skull. Silver staining was performed in order to assess physical axonal
damage. Slides were imaged using an Olympus BX50 brightfield microscope. The
corpus callosum was imaged and later assessed, visually, for positive silver staining.
Table 1. Table outlining the experimental plan for the Pilot Study.
Group #

Tests

Sample Size (n)

Timepoints

Age

I

IHC

2

naïve

2-3 month

II

IHC

3

10 day rmTBI

2-3 month
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2.11 Experiment 2: GSK3 Study

Figure 1. Timeline of the GSK3 Study. Timeline showing the various timepoints at
which the male C57BL/6 mice were sacrificed, along with their relative sample sizes
(n’s).

67 male C57BL/6 mice were used in this study, 6 naïve, 28 sham, and 33 rmTBI mice.
The outline of the experimental groups can be seen in both Figure 1 and Table 2. Mice
were sacrificed at various timepoints, after the last impact or sham procedure, and
Western blots were used to assess the total amount of GSK3β protein (GSK3 TOT), the
activation of GSK3β (pTyr216), and the inactivation of GSK3β (pSer9).

Data

organization was possible with the use of excel spreadsheets. Statistical analyses were
performed using Graphpad Prism 8, and data is presented as mean ± SEM. Western blot
data were analyzed using a One-way ANOVA test in order to compare across the
multiple time points that were assessed post-last injury.

Correction for multiple

comparisons was done using a Tukey’s post hoc test. Statistical significance was set as p
≤ 0.05.
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Table 2. Table outlining the experimental plan for the GSK3 Study.
Group #

Tests

Sample Size (n)

Timepoints

Age

I

Western blots

6 naïve

naïve

2-3 months

II, III

Western blots

6 sham, 7 rmTBI

8hr

2-3 months

IV, V

Western blots

4 sham, 7 rmTBI

24hr

2-3 months

VI, V11

Western blots

6 sham, 7 rmTBI

48hr

2-3 months

VIII, IX

Western blots

6 sham, 6 rmTBI

1wk

2-3 months

X, XI

Western blots

6 sham, 6 rmTBI

3wk

2-3 months
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2.12 Experiment 3: MAPT KI Study

Figure 2. Timeline of the MAPT KI Study. Timeline showing the various timepoints at
which the male and female MAPT KI mice were sacrificed, along with their relative
sample sizes (n’s).
102 MAPT KI mice were used in this study, 8 naïve, 46 sham, and 48 rmTBI mice. The
outline of the experimental groups can be seen in both Figure 2 and Table 3. Mice were
sacrificed at various timepoints, after the last impact or sham procedure, and various
immunohistochemical staining were used to assess cellular and molecular pathology.
Slides were imaged using an Olympus BX50 brightfield microscope and later assessed,
visually, for positive silver staining/immunohistochemical staining. Groups 9, 10, 13,
and 14 underwent evaluation through the use of various behavioural tests in order to
assess possible changes in behavioural outcomes post-injury in addition to the various
immunohistochemical staining. Data organization was possible with the use of excel
spreadsheets. Statistical analyses were performed using Graphpad Prism 8, and data is
presented as mean ± SEM. Elevated Plus Maze results were compared using unpaired
Student’s t-test. The Morris Water Maze learning curves were analyzed using a Twoway ANOVA, whereas the time spent in the quadrants was analyzed using a One-way
ANOVA. Correction for multiple comparisons was done using a Tukey’s post hoc test.
Statistical significance was set as p ≤ 0.05.
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Table 3. Table outlining the experimental plan for the MAPT KI Study.
Group #

Tests

I

IHC

Sample Size (n)
Male: 6 naïve

Timepoints
naïve

Female: 2 naïve

II

Age
Male: 5-6 months
Female: 5-6 months

III, IV

IHC

Male: 6 sham, 6 rmTBI

24hr

Male: 5-6 months

V, VI

IHC

Male: 6 sham, 6 rmTBI

1wk

Male: 5-6 months

V11, V111

IHC

Male: 6 sham, 6 rmTBI

4wk

Male: 5-6 months

Female: 10 sham, 10 rmTBI

XI, XII
IX, X

IHC

X111, XIV

EPM

Male: 7 sham, 8 rmTBI
Female: 11 sham, 12 rmTBI

Female: 3-5 months

10wk

Male: 3-5 months
Female: 3-5 months

MWM
7 aged MAPT KI mice (5 males and 2 females) and 3 aged C57BL/6 mice (2 males and 1
female) were used in this study. The outline of the experimental groups can be seen in
Table 4. Slides were imaged using an Olympus BX50 brightfield microscope and later
assessed, visually, for positive silver staining/immunohistochemical staining.
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Table 4. Table outlining the experimental plan for the aged MAPT KI and C57BL/6
mice.
Group #

Tests

Sample Size (n)

Age

Strain, Sex

I

IHC

5

14 months

MAPT KI, male

II

IHC

1

12 months

MAPT KI, female

III

IHC

2

14 months

C57BL/6, male

IV

IHC

1

14 months

C57BL/6, female
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Chapter 3
3

Results

3.1

Pilot Study: To validate a closed head, closed skin model
of rmTBI

The goal of this thesis was to characterize a mouse model of concussion that is as
clinically relevant as possible. In order to accomplish this, it was important that both the
skull and the skin of the mice remained intact during the entire procedure. Previously
reported models of TBI in mice were either open skull, requiring a craniotomy (Popovitz
et al., 2019) or a craniectomy (Giarratana et al., 2019), or closed skull but open skin
(Bolton & Saatman, 2014; Rehman et al., 2019; Xu et al., 2021). While these methods
have the advantage of allowing the site of injury to be precisely located, the fact that the
skull and skin are not intact in these models makes them less clinically relevant than
desired. The Brown laboratory has previously characterized a closed skull, open skin
model of rmTBI in C57BL/6 mice (Xu et al., 2021). In this model, mice were placed in a
Kopf mouse anesthesia mask under a traumatic brain injury device (TBI 0310, Precision
Systems and Instrumentation, LLC). Following a 10 mm midline incision, the skin and
fascia were reflected. Then the mice received a mild controlled cortical impact directly
onto the skull, centered on the bregma, with a custom-made, 4mm-diameter pliant
silicone tip. The impact device was programmed to impact at a depth of 1.0 mm at a
velocity of 3.5 m/sec with a 500 millisecond dwell time. Each mouse in that study
received 5 mTBIs (one a day for 5 consecutive days). The purpose of this pilot study was
to determine if the same injury protocol, without the skin incision, would produce a
similar level of injury as the open skin rmTBI as assessed by silver staining of the brain
to detect diffuse axonal injury.
C57BL/6 mice (n = 3) were subjected to 5 mTBIs (one a day for 5 days) and sacrificed 10
days post-last injury. A group of unmanipulated mice (n = 2) acted as naïve controls. An
examination of tissue sections from injured and naïve mice demonstrated that the injured
mice had significant levels of silver stained axons within the corpus callosum (Figure 3C)
and even more so in the optic tract (Figure 3D) compared to the naïve controls (Figure
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3A and B). When compared to the mice injured in the same way but with the scalp
reflected away (Figure 3E and F), there was less silver staining in the corpus callosum
and more robust staining in the optic tract. This suggested that the rmTBI with closed
skin produces a similar injury as the open skin injury with the impact device settings of
1.0 mm depth, 3.5 m/sec velocity and 500 millisecond dwell time, just in different
regions of the brain. Therefore, the rmTBI with the skin intact, was shown to produce
sufficient physical damage, as assessed by the silver staining.
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Figure 3. Silver staining during the pilot study. (A) Silver staining of the corpus callosum
of a naïve animal (n=2). (B) Silver staining of the optic tract of a naïve animal. (C) Silver
staining of the corpus callosum of a closed skin injured animal (n=3). (D) Silver staining
of the optic tract of a closed skin injured animal. (E) Silver staining of the corpus
callosum of an open skin injured animal. (F) Silver staining of the optic tract of an open
skin injured animal. All images were taken at 40x.
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3.2

Aim #1: To determine the kinetics of GSK3β
phosphorylation post-rmTBI in the C57BL/6 mice

GSK3β has been identified as a kinase critical to the pathological phosphorylation of tau
(Hooper et al., 2008; Moszczynski et al., 2018). In vitro GSK3β inhibition prevents
pathological tau phosphorylation and promotes cell survival (Moszczynski et al., 2015).
The regulation of GSK3β depends on the phosphorylation status of two regulatory sites,
Tyr216 and Ser9. When Tyr216 becomes phosphorylated (pTyr216), the activity of
GSK3β is increased, however, when Ser9 becomes phosphorylated (pSer9), the activity
of the kinase is blocked (Soutar et al., 2010). As one of the ultimate goals of this model
development, to test whether GSK3 inhibition may be a strategy to prevent pathological
tau accumulations in the concussed brain, we sought to describe the kinetics of GSK3β
phosphorylation on both the Tyr216 and the Ser9 sites at various time points after rmTBI.
In this study Western blots were used to assess the levels of GSK3β protein (GSK3
TOT), pTyr216, and pSer9 in the cortex and hippocampus of naïve, sham, and rmTBI
mice (n= 4-7 per group). The levels of GSK TOT, pTyr216 and pSer9 were analyzed
relative to the levels of -actin. The levels of pTyr216 and pSer9 were also analyzed as a
ratio to GSK TOT.
Western blot analyses of cortical samples when protein levels were normalized to -actin
Western blot analyses of total amount of GSK3β protein in naïve, sham and rmTBI
cortices revealed that the levels of GSK3 TOT were higher in shams than in naïves at 8 h
and 1 week post-injury (Figure 4A). Similarly, the levels of GSK3 TOT were higher in
rmTBI mice than in naïves at 8 h, 1 week and 3 week post-injury (Figure 4A). The
Western blot analyses also showed higher pTyr216 levels in both shams and rmTBI mice
compared to naïves across all time points with the exception of shams at 8 h postprocedure (Figure 4B). The Western blot analyses also showed increased levels of pSer9
in shams at 3 weeks post-procedure compared to naïves and at 48 h and 3 week postinjury in the rmTBI group compared to naïves (Figure 4C). There were no time points at
which GSK TOT or pTyr216 levels were significantly different between sham and rmTBI
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mice, however, pSer9 levels were significantly higher in rmTBI mice compared to shams
at 48 h post-injury.

Figure 4. Western blot data for the cortex samples across all timepoints. (A) Graph
shows all treatment groups (naïve, sham and injured) for each timepoint looking at the
total amount of GSK3β, GSK3 TOT, relative to β-actin and then compared to the naïve
sample. (B) Graphs focus on the amount of phosphorylation at the Tyr216 site on GSK3β
relative to β-actin and then compared to the naïve sample. (C) Graphs focus on the
amount of phosporylation at the Ser9 site on GSK3β relative to β-actin and then
compared to the naïve sample. (D) Respresentative Western blots (n=naïve, s=sham,
h=hit). Data were presented as mean±SEM. SEM was presented as the error bars. Oneway ANOVA statistical tests were performed with Tukey’s multiple comparisons test,
p<0.05. “*” represents treatment groups that significantly differ from the naïve animals.
“#” represents significant differences between the sham and injured groups of the same
timepoint.
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Western blot analyses of hippocampal samples when protein levels were normalized to actin
Western blot analyses of total amount of GSK3β protein in naïve, sham and rmTBI
hippocampi revealed that the levels of GSK3 TOT were higher in sham and rmTBI
hippocampi than in naïve hippocampi at 24 h post-injury or sham procedure (Figure 5A).
The Western blot analyses also showed higher pTyr216 levels in both shams and rmTBI
mice compared to naïves across all time points with the exception of the 3 week time
point post-procedure (Figure 5B). Compared to naïves the levels of pSer9 was higher in
shams at 48 h and 1 week post-sham procedure and in rmTBI mice at 1 week post-injury
(Figure 5C). There were no time points at which GSK TOT or pTyr216 levels were
significantly different between sham and rmTBI mice, however, pSer9 levels were
significantly lower in rmTBI mice compared to shams at 1 week post-injury.
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Figure 5. Western blot data for the hippocampal samples across all timepoints. (A)
Graph shows all treatment groups (naïve, sham and injured) for each timepoint looking at
the total amount of GSK3β, GSK3 TOT, relative to β-actin and then compared to the
naïve sample. (B) Graphs focus on the amount of phosphorylation at the Tyr216 site on
GSK3β relative to β-actin and then compared to the naïve sample. (C) Graphs focus on
the amount of phosporylation at the Ser9 site on GSK3β relative to β-actin and then
compared to the naïve sample. (D) Respresentative Western blots (n=naïve, s=sham,
h=hit). Data were presented as mean±SEM. SEM was presented as the error bars. Oneway ANOVA statistical tests were performed with Tukey’s multiple comparisons test,
p<0.05. “*” represents treatment groups that significantly differ from the naïve animals.
“#” represents significant differences between the sham and injured groups of the same
timepoint.
Western blot analyses of cortical samples when protein levels were normalized to GSK


To evaluate the relative level of GSK3 activation in the cortex we also examined the
ratio of pTyr216 levels to GSK TOT levels in cortical protein samples. These analyses
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revealed that the levels of pTyr216, when normalized to GSK TOT levels, was
significantly reduced by approximately 2-fold, in sham and rmTBI mice compared to
naïves at all time points studied (except for the shams at 3 week post-procedure) (Figure
6A). To evaluate the relative level of GSK3 inhibition we also examined the ratio of
pSer9 levels to GSK TOT levels in cortical protein samples. We found that pSer9 levels
in sham mice, when normalized to GSK TOT levels were significantly reduced (by 5 – 10
fold) compared to naïves at 8 h, 24 h, 48 h and 1 week post-procedure (Figure 6B). The
pSer9 levels in the rmTBI mice, when normalized to GSK TOT levels, were significantly
reduced (by 5 – 10 fold) compared to naïves at 8 h and 24 h, post-injury (Figure 6B).
Western blot analyses of hippocampal samples when protein levels were normalized to
GSK 
To evaluate the relative level of GSK3 activation in the hippocampus we examined the
ratio of pTyr216 levels to GSK TOT levels in the hippocampal protein samples.

This

analyses revealed that the levels of pTyr216, when normalized to GSK TOT levels, was
significantly reduced by approximately 4-5-fold, in sham and rmTBI mice compared to
naïves at all time points studied (except for the 3 week post-injury or procedure time
point) (Figure 6C). To evaluate the relative level of GSK3β inhibition we also examined
the ratio of pSer9 levels to GSK TOT levels in cortical protein samples. We also found
that pSer9 levels in sham mice, when normalized to GSK TOT levels were significantly
reduced (by 25 - 100 fold) compared to naïves at all time points (Figure 6D).
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Figure 6. Western blot data comparing the amount of phosphorylation at the regulatory
sites on GSK3β to the total amount of GSK3β protein. (A) Cortex samples for all
treatment groups across all the timepoints analyzed focusing on the amount of
phosphorylation at the Tyr216 regulatory site, relative to the total amount of protein. (B)
Cortex samples for all treatment groups across all the timepoints analyzed focusing on
the amount of phosphorylation at the Ser9 regulatory site, relative to the total amount of
protein. (C) Hippocampus samples for all treatment groups across all the timepoints
analyzed focusing on the amount of phosphorylation at the Tyr216 regulatory site,
relative to the total amount of protein. (D) Hippocampus samples for all treatment
groups across all the timepoints analyzed focusing on the amount of phosphorylation at
the Ser9 regulatory site, relative to the total amount of protein. (E) Hippocampus
samples from (D) excluding the naïve animals. Data were presented as mean±SEM.
SEM represented as the error bars. One-way ANOVA statistical tests were performed
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with Tukey’s multiple comparisons test, p<0.05. “*” represents treatment groups that
significantly differ from the naïve animals. “#” represents significant differences between
the sham and injured groups of the same timepoint.

3.3

Aim #2: To characterize the cellular and molecular
pathology triggered by rmTBI in the MAPT KI mice

MAPT KI mice
As discussed in the introduction to this thesis (Chapter 1, pages 1-23), using MAPT KI
mice to study rmTBI increases the clinical relevance of this model of rmTBI. The MAPT
KI mice carry a fully humanized tau gene in place of the murine tau gene. Thus,
pathological consequences of concussion due to the effects of rmTBI on tau would be
predicted to be more reflective of human pathological changes consequent to concussion
in the MAPT KI mice compared to C57BL/6 mice.
A COVID19 impact note concerning the histopathological and behaviour analyses below
During the analyses phase of this study it became apparent that the controlled cortical
impactor was not performing up to specifications, despite being calibrated by myself and
others in the laboratory. There was a problem with the impactor itself, in that the speed
and/or depth programming of the machine was incorrect and highly variable. The
impactor was sent back to the company (Precision Instruments) for recalibration but was
damaged in transit back to the Robarts Research Institute and we now are awaiting a
replacement. I wanted to repeat the experiment with a properly calibrated impactor
however, the combined effects of the COVID-19 restrictions on animal work instituted in
March of 2020 and the impactor malfunction delayed my progress by 6 – 8 months
making it impossible for me to repeat. Thus, I present my findings below with the
admission that there was great variability in the injuries carried out in the MAPT KI
mice that makes interpretations of the data challenging at best. However, I carried out
the histopathological and behavioural analyses to the best of my ability and have, at the
very least, provided baseline measurements for shams and naïves that will be useful when
this project continues upon receipt of a new impactor.
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Histopathological analyses
To assess MAPT KI mice for histological changes after rmTBI that reflect diffuse axonal
injury (DAI) we performed silver staining of brain sections from MAPT KI mice taken at
various time points after injury using the FD NeurosilverTM Kit II silver staining kit (FD
NeuroTechnologies, Ellicott City, MD) as previously described (Xu et al., 2021). Images
of the corpus callosum were taken using a brightfield microscope at 40x and were
visually inspected for black silver staining (Figure 7-10).
Short term analyses (naïve, 1 and 7 days)
Naïve animals had no intervention during the experiment, and as expected, had no
evidence of silver stained axons when looking at the corpus callosum (Figure 7A). At 1
day and 7 days post-injury, brain sections from injured male MAPT KI (Figure 7C and E)
demonstrated some silver staining, compared to shams (Figure 7B and D) that was
particularly evident at high power magnification (insets in Figure 7C and E).
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Figure 7. Silver staining for the short term timepoints of the MAPT KI study. (A) Silver
staining of the corpus callosum of a naïve animal (n=6). (B) Silver staining of the corpus
callosum of a sham animal sacrificed at the 1 day timepoint. (C) Silver staining of the
corpus callosum of an injured animal sacrificed at the 1 day timepoint. (D) Silver
staining of the corpus callosum of a sham animal sacrificed at the 7 day/1 week
timepoint. (E) Silver staining of the corpus callosum of an injured animal sacrficed at the
7 day/1 week timepoint. All images were taken at 40x.
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Long term analyses (4 and 10 weeks)
Sections from both male and female injured MAPT KI mice demonstrated some silver
staining at 4 and 10 week post-injury compared to their sham counterparts (Figure 8).
High power magnifications showed that the silver stained axons had the characteristic
tortuous appearance suggestive of axonal damage (Shitaka et al., 2011).

Figure 8. Silver staining for the longer term timepoints of the MAPT KI study. (A) Silver
staining of the corpus callosum of a sham male sacrificed at the 4 week timepoint. (B)
Silver staining of the corpus callosum of an injured male sacrificed at the 4 week
timepoint. (C) Silver staining of the corpus callosum of a sham female sacrificed at the 4
week timepoint. (D) Silver staining of the corpus callosum of an injured female
sacrificed at the 4 week timepoint. (E through H) Same order of images as the ones
above, except taken from the animals sacrifced at the 10 week timepoint. All images were
taken at 40x.
Variability in injury
While the histopathological staining of rmTBI MAPT KI mice showed the presence of
silver-stained axons their number per section seemed greatly reduced compared to the
number of silver-stained axons in the pilot project described above. Furthermore, we also
observed a great degree of variability in the amount of silver staining in different mice.
This variability can be seen in the images in Figure 9. Figure 9 shows the results of silver
staining in sections from 4 different males and 4 different females 10 weeks after their
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injury. Despite receiving the same injury, the silver staining revealed great variability in
the number of silver stained axons between animals. Most of the animals studied had
minimal silver staining (Figure 9A, B, C, E, F and G) suggesting lighter concussive hits,
whereas a handful of injured animals had greater amounts of silver staining suggesting
that they sustained more severe injuries (Figure 9D and H), resulting in more pathology.
Naïve animals did not show signs of positive silver staining. This histopathology was the
first inkling that the impactor was malfunctioning – a problem that was subsequently
verified and prompted a return of the impactor to Precision Instruments for recalibration
and repair.

Figure 9. Silver staining of the variabliltiy of the injuries delivered by the controlled
cortical impactor (CCI). (A through D) Snippets of the corpus callosum of the injured
male animals sacrifficed at the 10 week timpoint. (E through H) Snippets of the corpus
callosum of the injured females sacrifced at the 10 week timepoint. Images on the left
most side have negligible silver staining and as the images move towards the right most
side there is significant amounts of silver staining. Images in the middle vary in the
degree of silver staining. Images were taken at 40x.
Silver staining in sections from Aged MAPT KI mice
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI
there was a need to establish baseline histopathological measures in uninjured aged
MAPT KI mice. All aged animals received no intervention during these experiments.
Male MAPT KI mice were raised until they reached 14 months of age and were then
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sacrificed. A single female MAPT KI mouse was raised until it reached 12 months of age
and was then sacrificed. Greater numbers of MAPT KI mice were not available due to
COVID-19 restrictions on animal breeding. Both aged male and female MAPT KI mice
displayed minimal silver staining (Figure 10A and B) that was comparable to the amount
of silver staining observed in aged (14 month old) C57BL/6 mice (Figure 10C and D).

Figure 10. Silver staining of the aged animals. (A) Silver staining of the corpus callosum
of an aged MAPT KI male sacrificed at 14 months old. (B) Silver staining of the corpus
callosum of an aged MAPT KI female sacrificed at 12 months old. (C) Silver staining of
the corpus callosum of an aged C57BL/6 male sacrificed at 14 months old. (D) Silver
staining of the corpus callosum of an aged C57BL/6 female sacrificed at 14 months old.
All images were taken at 40x.
Staining for pathologically phosphorylated tau in injured MAPT KI animals
Abnormal phosphorylation of tau has been reported in human brain samples from
subjects with a history of concussion (McKee et al., 2009, 2013; Tagge et al., 2018) and
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in rmTBI mice (Tagge et al., 2018; Xu et al., 2021). To characterize the levels of
pathologically phosphorylated tau in rmTBI MAPT KI mice we immunostained sections
from naïve, sham and rmTBI mice at 10 weeks post-injury or sham procedure with the
AT8 antibody that recognizes phospho-tau (Ser202, Thr205) (Y. Zhang et al., 2019).
Figure 11 shows a series of photomicrographs taken in the cortical/prefrontal areas of
these sections. Naïve male MAPT KI did not display positive AT8 staining (Figure 11D).
Injured male MAPT KI mice (Figure 11F) had significantly more AT8 positive staining
compared to the shams (Figure 11E) and the naïve animals (Figure 11D) that was
comparable to the AT8 staining seen in C57BL/6 rmTBI mice (Figure 11C).

Figure 11. AT8 staining in the prefrontal cortex of the injured animals. (A)
Representative ATLAS image of the brain sections that were stained and imaged. The
black box represents the approximate area in which the photos were taken. AT8 staining
is red and DAPI staining is blue. (B) Image of a C57BL/6 sham animal donated by Dr.
Kathy Xu for comparison to the MAPT KI. (C) Image of a C57BL/6 injured animal
donated by Dr. Kathy Xu for comparison to the MAPT KI. (D) Image of a naïve MAPT
KI animal. (E) Image of a sham MAPT KI animal. (F) Image of an injured MAPT KI
animal. Numbers in the top right corner represent the n’s for each group. All images
were taken at 40x.
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Staining for pathologically phosphorylated tau in uninjured aged MAPT KI animals
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI
there was also a need to establish baseline levels for pathologically phosphorylated tau in
aged MAPT KI mice. We immunostained brain sections from aged uninjured MAPT KI
mice with the AT8 antibody. Figure 12 shows photomicrographs taken from the
cortical/prefrontal areas of these sections (Figure 12A).

Aged animals were not

manipulated and left to age naturally over the course of this experiment. C57BL/6 male
and female mice were aged to 14 months old, male MAPT KI mice were aged to 14
months old, and the sole female MAPT KI mouse was aged to 12 months. Naïve animals
did not show any positive AT8 staining (Figure 12D). Uninjured, aged male and female
C57BL/6 mice showed minimal AT8 staining (Figure 12B and C), whereas uninjured,
aged male and female MAPT KI mice demonstrated more AT8 positive staining (Figure
12E and F).
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Figure 12. AT8 staining in the prefrontal cortex of the aged animals. (A) Representative
ATLAS image of the brain sections that were stained and imaged. The black box
represents the approximate area in which the photos were taken. AT8 staining is red and
DAPI staining is blue. (B) Image of an aged C57BL/6 male sacrificed at 14 months old.
(C) Image of an aged C57BL/6 female sacrificed at 14 months old. (D) Image of a naïve
MAPT KI animal. (E) Image of an aged MAPT KI male sacrificed at 14 months old. (F)
Image of an aged MAPT KI female sacrificed at 12 months old. Numbers in the top right
corner represent the n’s for each group. All images were taken at 40x.
Inflammation in the MAPT KI mice after rmTBI
To determine if the inflammatory response triggered by rmTBI in MAPT KI mice was
similar to that triggered in rmTBI C57BL/6 mice we immunostained brain sections from
rmTBI (C57BL/6 and MAPT KI) mice for GFAP and Iba1.

Figure 13 shows

photomicrographs from the cortex of these stained sections (Figure 13A). Injured male
C57BL/6 and MAPT KI (Figure 13C and H) mice displayed increased levels of Iba1
immunostaining compared to sham animals (Figure 13B, D, G and J). Naïve male MAPT
KI mice (and C57BL/6 mice, data not shown) did not show any significant Iba1 staining
(Figure 13F), but did show moderate GFAP staining (Figure 13I) as did sections from
sham (Figure 13D and J) and rmTBI mice (Figure 13E and K).
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Figure 13. GFAP and Iba1 staining in the corpus callosum area for the injured animals.
(A) Representative ATLAS image of the brain sections that were stained and imaged.
The black box represents the approximate area in which the photos were taken. GFAP
staining is green, Iba1 staining is red and DAPI staining is blue. (B and D) Images of the
GFAP and Iba1 staining for a C57BL/6 sham animal donated by Dr. Kathy Xu. (C and E)
Images of the GFAP and Iba1 staining for a C57BL/6 injured animal donated by Dr.
Kathy Xu. (F and I) Images of the GFAP and Iba1 staining for a naïve MAPT KI animal.
(G and J) Images of the GFAP and Iba1 staining for a sham MAPT KI animal. (H and K)
Images of the GFAP and Iba1 staining for an injured MAPT KI animal. Numbers in the
top right corner represent the n’s for each group. All images were taken at 40x.
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What does the GFAP and Iba1 staining look like in uninjured aged MAPT KI mice
To fully characterize the usefulness of the MAPT KI mice for chronic studies of rmTBI
we investigated the baseline GFAP and Iba1 levels in brain sections from uninjured aged
MAPT KI mice. Brain sections from uninjured, aged MAPT KI mice were immunostained
for GFAP and Iba1 expression. Figure 14 shows photomicrographs taken from the cortex
of these sections (Figure 14A). While aged, uninjured C57BL/6 and MAPT KI mice
demonstrated very little Iba1 expression (Figure 14B, C, G and H) they did demonstrate
moderate levels of GFAP immunostaining (Figure 14D, E, I, J and K).
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Figure 14. GFAP and Iba1 staining in the corpus callosum area for the aged animals. (A)
Representative ATLAS image of the brain sections that were stained and imaged. The
black box represents the approximate area in which the photos were taken. GFAP
staining is green, Iba1 staining is red and DAPI staining is blue. (B and D) Images of the
GFAP and Iba1 staining of an aged C57BL/6 male. (C and E) Images of the GFAP and
Iba1 staining of an aged C57BL/6 female. (F and I) Images of the GFAP and Iba1
staining for a naïve MAPT KI animal. (G and J) Images of the GFAP and Iba1 staining of
an aged MAPT KI male. (H and K) Images of the GFAP and Iba1 staining of an aged
MAPT KI female. Numbers in the top right corner represent the n’s for each group. All
images were taken at 40x.
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3.4

Aim #3: To characterize the behavioural outcomes
triggered by rmTBI in the MAPT KI mice

The effects of rmTBI on behaviour of MAPT KI mice in the elevated plus maze
It has been previously shown that rmTBI can be associated with anxiety and anxiety-like
behaviours post-injury (Broussard et al., 2017). We sought to investigate the potential
effects of rmTBI on anxiety/anxiety-like behaviours at 8.5 weeks post-injury in the
MAPT KI mice using the Elevated Plus Maze (EPM) test. Mice were placed into the
centre portion of the maze and allowed to freely explore the maze as their behaviours
were videotaped for five minutes. The amount of time each mouse spent in the closed
arms, open arms, and in the centre of the maze was measured by ANY-Maze (Stoelting
Co. Wood Dale, IL). Male rmTBI MAPT KI mice spent a significantly longer amount of
time in the closed arms compared to the shams (Figure 15A), which spent more time in
the open arms of the maze (Figure 15B). There were no significant differences in the
amount of time spent in the centre part of the maze (Figure 15C). There were no
significant differences in the mean speed, and total distance travelled between the male
sham and rmTBI MAPT KI mice (Figure 16A and B).
An analysis of female rmTBI and sham MAPT KI mice demonstrated there were no
significant differences in the amount of time spent in the closed and open arms of the
maze (Figure 15D and E), however, there were significant differences in the amount of
time spent in the centre part of the maze (Figure 15F). The female rmTBI mice spent a
significantly longer time in the centre of the maze compared to shams. There were
significant differences in the mean speed and total distance travelled (Figure 16C and D)
with the female sham mice travelling at a faster mean speed than the injured females and
travelling a greater distance within the EPM compared to injured individuals.
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Figure 15. Behavioural data from the Elevated Plus Maze (EPM) Test. (A) Time spent in
the closed arms of the EPM for sham and injured MAPT KI males. (B) Time spent in the
open arms of the EPM for sham and injured MAPT KI males. (C) Time spent in the
centre area of the EPM for sham and injured MAPT KI males. (D) Time spent in the
closed arms of the EPM for sham and injured MAPT KI females. (E) Time spent in the
open arms of the EPM for sham and injured MAPT KI females. (F) Time spent in the
centre area of the EPM for sham and injured MAPT KI females. Data were presented as
mean±SEM. SEM was represented as the error bars. “*” represents significant
differences between the treatment groups. Student’s t-test was performed for the EPM
data, p<0.05
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Figure 16. Mean speed and total distance travelled in the Elevated Plus Maze (EPM)
Test. (A) Mean speed of sham and injured MAPT KI males. (B) Total distance travelled
for sham and injured MAPT KI males. (C) Mean speed of sham and injured MAPT KI
females. (D) Total distance travelled for sham and injured MAPT KI females. Data were
presented as mean±SEM. SEM was represented as the error bars. “*” represents
significant differences between the treatment groups. Student’s t-test was performed for
the EPM data, p<0.05

How does rmTBI influence spatial cognition and memory of MAPT KI mice?
Repetitive mTBI has been previously linked to spatial cognition and memory deficits
using the Morris Water Maze test (MWM) (Mannix et al., 2014; Xu et al., 2021). The
effects of rmTBI on spatial cognition and memory in male and female MAPT KI mice
were assessed with the MWM. Male sham and rmTBI MAPT KI mice had difficulty
learning the task, as demonstrated by the learning curves in Figure 17A [F(3,48)=1.849,
p=0.1510]. During the Probe Trial, conducted on Day 5, there were no significant
differences in the amount of time spent in the target quadrant versus non-target quadrants
as assessed by one-way ANOVA (Figure 17B). There was a significant difference seen
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in the mean swim speeds (m/sec) during the Probe Trial, with the injured males
swimming significantly faster than the sham males (Figure 17C).
The learning curves for the female sham and rmTBI MAPT KI mice demonstrate that
both groups were able to learn the task, with no significant differences in learning
between groups throughout the four training days (Figure 17D). On the Probe Trial there
were no significant differences in the amount of time spent in the target quadrant versus
non-target quadrants as assessed by one-way ANOVA (Figure 17E), for sham or rmTBI
MAPT KI females. There were no significant differences for swim speeds between
groups during the Probe Trial (Figure 17F).

Figure 17. Behavioural data from the Morris Water Maze (MWM) Test. (A) Escape
latency for each of the four training days of the MWM for both sham and injured MAPT
KI males. (B) Time spend in both the non-target (Q1-3) and target (Q4) quadrants of the
MWM during the probe trial for both sham and injured MAPT KI males. (C) Mean swim
speed for sham and injured MAPT KI males. (D) Escape latency for each of the four
training days of the MWM for both sham and injured MAPT KI females. (E) Time spend
in both the non-target (Q1-3) and target (Q4) quadrants of the MWM during the probe
trial for both sham and injured MAPT KI females. Data were presented as mean±SEM.
SEM was represented as the error bars. “*” represents significant differences between the
treatment groups. One-way ANOVA statistical tests were performed for A, B, D, and E
with Tukey’s multiple comparisons test. Student’s t-test were performed for C and F,
p<0.05.
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Chapter 4
4

Discussion and Conclusions

The objectives of this study were to characterize a time course of GSK3β
phosphorylation, using C57BL/6 mice, and to investigate the cellular/molecular
pathology and behavioural outcomes in MAPT KI mice in order to validate their
usefulness in concussion research as a more clinically relevant model. This study is
going to be one of few, if not the first of its kind, to use the MAPT KI transgenic mice
created from Saito et al. (2019) in a model of repetitive mild traumatic brain injury.

4.1

Pilot Study

Before the study began, a pilot study was conducted in order to determine if the same
injury protocol, minus the skin incision, would produce similar injury levels compared to
the injury protocol including the skin incision previously used by the Brown Lab (Xu et
al., 2021). Silver staining revealed that both injury protocols produced abundant positive
silver staining, but in different areas of the brain (Figure 3), proving that keeping the skin
intact with the same injury parameters was sufficient to cause physical axonal damage.
Clearly, the protocol excluding the skin incision was sufficient to produce some level of
injury as indicated by the silver staining, however, in the future, there could be room for
improvement. For instance, the parameters of the hit could be adjusted to account for the
thickness of the skin and/or adjust the intensity of the injury delivered. One study
investigating the physical and mechanical properties of mammalian skin in various
animal models determined that smaller species, such as rodent models, have increased
viscoelastic effects in the skin compared to larger species, such as humans (Wei et al.,
2017). Other factors can also influence the properties of the skin, such as age, gender,
and weight (Wei et al., 2017). In terms of the actual injury parameters, both the depth
and the speed of the injury delivered could be adjusted in order to increase the severity of
the hit. This could be done by increasing the depth or by increasing the speed, or by
increasing both parameters at the same time.

62

4.2

Kinetics of GSK3β Phosphorylation triggered by rmTBI

After an episode of rmTBI, many cascades are initiated that result in neurodegenerative
changes that lead cognitive deficits. It has been proposed that GSK3β is responsible for
the abnormal phosphorylation of tau in tauopathies, such as CTE (Hooper, Killick, and
Lovestone, 2008). This abnormal phosphorylation of tau is what causes the pathological
formation of aggregates/fibrils/tangles leading to neuronal death (Polydoro et al., 2009).
Moszczynski et al (2018) demonstrated this process, in a rodent model of moderate TBI,
showing that both the activation of GSK3β and tau pathology were increased 3 months
post-injury. Many studies have evaluated the effects of preventing the activation of
GSK3β and abnormal tau phosphorylation (Dash et al., 2011). To plan how we might
best deliver a GSK3β inhibitor we sought to determine when and for how long, after
rmTBI, GSK3β is activated. In my study, several time points post-injury were analyzed
to investigate the levels of phosphorylation on two of the main regulatory sites on
GSK3β, pTyr216 and pSer9 (Fang et al., 2000; Krishnankutty et al., 2017), relative to
total GSK3β. Western blot analyses revealed that in both the cortical and hippocampal
protein samples GSK3 TOT levels when normalized to β-actin were increased in rmTBI
mice compared to naïves at several timepoints (Figure 4 and 5). When looking at the
relative phosphorylation on the regulatory sites compared to total GSK3β protein (Figure
6), there is a higher ratio of pTyr216/GSK3 TOT compared to pSer9/GSK3 TOT, and,
taken together with the increase in total GSK3β protein, these results suggest that there
may be increased activation of GSK3β in the rmTBI groups.

However, these two

regulatory sites are not the only regulatory mechanisms acting on GSK3β. For example,
there is another known inhibitory site on GSK3β, Ser389, that is phosphorylated by p38
mitogen-activated protein kinase (MAPK) (Thornton et al., 2008). In order to assess the
actual activity of GSK3β, kinase activity assays would need to be conducted, similar to
that seen in the Noble et al. study (Noble et al., 2005). In the future, one could also
assess the activity of multiple activation and inactivation pathways that converge on
GSK3β in order to get a clearer, more complete picture as to how active GSK3β actually
is during pathological processes. Two of the main signaling pathways that result in the
inactivation of GSK3 proteins are the insulin and Wnt pathways (Beurel et al., 2015).
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GSK3β also requires substrate priming for the majority of its known substrates. Priming
of target substrates is a method of controlling the specificity and targeting action of
GSK3β (Fiol et al., 1987). This priming mechanism involves the phosphorylation of
GSK3β substrates by another kinase at approximately 4 residues away from the target site
for GSK3β phosphorylation (Frame & Cohen, 2001). Therefore, it would be of great
interest to investigate the priming kinases that phosphorylate before GSK3β, as these
kinases must act first in order for GSK3β to perform the subsequent phosphorylation(s)
(Frame & Cohen, 2001).
Another method of assessing the contribution of GSK3β to the development of
pathological hallmarks of disease would be to conduct inhibitory trials where the activity
of GSK3β is hindered or completely blocked. A potential candidate GSK3β inhibitor,
such as lithium, could be administered in order to mitigate these pathological
mechanisms/pathways from occurring and deter cognitive impairments associated with
multiple mild traumatic head injuries (concussions) (Dash et al, 2011). In a cell culture
experiment using Neuro2A cells, Moszczynski et al (2015) demonstrated that lithium
treated cultures showed reduced GSK3β activity, decreased tau phosphorylation,
reducing fibril formation and cell death.
It is worthy to note that other tau kinases may be responsible and contribute to the
abnormal phosphorylation of tau. Each kinase involved in the phosphorylation of tau
phosphorylates specific target sites that consequently result in unique physiological
effects, some of which may be pathological (Dolan & Johnson, 2010). For example, a
study investigating paired helical filament tau (PHF-tau) using mass spectrometry found
that casein kinase 1 delta (CK1δ) phosphorylated approximately 15 sites implicated in
PHF-tau (Hanger et al., 2007).

The number of sites that CK1δ was capable of

phosphorylating on PHF-tau was comparable to that of GSK3β in this study,
demonstrating that other tau kinases, or synergistic relationships between tau kinases,
might be implicated in the generation of pathological tau aggregates (Hanger et al.,
2007). Another kinase that may phosphorylate tau is cyclin dependent kinase 5 (cdk5)
(Baumann et al., 1993). In this study, investigators evaluated cyclin dependent kinase
(cdk) family members that are expressed within the brain and found a cdk-like kinase that
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was able to phosphorylate tau in a similar manner to pathological tau present in
Alzheimer’s disease (AD) (Baumann et al., 1993). They discovered cdk5, confirming its
presence with the use of cdk5 specific antibodies, and proposed that this kinase be
considered as a serious contender for potential pathological phosphorylation of tau. Fyn,
a tyrosine kinase, is also capable of phosphorylating human tau (at the tyrosine 18
(Tyr18) residue) (G. Lee et al., 2004).

Fyn has been shown to co-localize with

pathologically phosphorylated tau protein, in particular, PHF-tau that reacts positively
with antibodies targeting the Tyr18 site (G. Lee et al., 2004). Therefore, Fyn is another
important candidate for causing or contributing to the abnormal phosphorylation of tau.
It is important to recognize that both the sham and injured mice in this study displayed
similar changes in the phosphorylation status of the two regulatory sites.

It was

discovered, upon conducting a literature search, that the anesthetic that was used in this
study, isoflurane, is capable of influencing the phosphorylation status of GSK3 proteins.
One study, investigating the effects of anesthetics on global protein phosphorylation in
adult mouse hippocampi, found that there were 318 significant phosphorylation events
with respect to 237 different proteins, one of which was GSK3β (Kohtala et al., 2016).
Another study using a rat model of Parkinson’s Disease (PD) that was investigating the
effects of brief isoflurane exposure on the phosphorylation of GSK3β, found that there
were increased levels of Ser9 phosphorylation in both the cortex and the striatum of the
rats (Leikas et al., 2017). The effects of the isoflurane must be taken into account when
designing and conducting experiments due to the confounding effects of its use.
Appropriate experimental design must include shams for each timepoint analyzed in
order to better distinguish between the effects of the anesthetic and the effects of the
treatment.

4.3

Characterization of Cellular and Molecular Pathology
triggered by rmTBI

In order to validate a clinically relevant model of concussion, rmTBI, we investigated
whether the closed skin injury delivered by the CCI device generated diffuse axonal
injury (DAI) using silver stained sections from rmTBI MAPT KI mice. In terms of the
short term timepoints investigated (naïve animals, 1 day and 7 day timepoints), and the
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long term timepoints (4 weeks and 10 weeks), the silver staining showed little positive
silver staining in the injured groups compared to the shams, which is less than we were
expecting (Figure 7 and 8). The variability in the injuries delivered by the CCI device
can be seen in Figure 9, in which the level of silver staining in injured mice vary from
very low levels to high levels of silver staining, despite the fact that all animals
underwent the same injury protocol. These highly variable results may be explained by
the fact that the controlled cortical impactor device that I was using throughout the MAPT
KI study had been malfunctioning, despite being calibrated by myself and others in the
lab. Although the outputs that were being read out by the machine itself were the desired
parameters of the study, it was obvious that the machine was not matching those
parameters, when the results were being analyzed, and the machine was then sent out to
be re-calibrated.

Therefore, the rmTBI mice in this study experienced inconsistent

injuries of variable severity – a fact that must be kept in mind when interpreting the
results.
When investigating the pathologically phosphorylated tau, recognized by the AT8
antibody that recognizes phospho-tau at Ser202/Thr205 (Invitrogen), both 10 week
injured MAPT KI and C57BL/6 male mice were analyzed. Images were chosen to
represent the average amount of staining for each group analyzed.

Pathologically

phosphorylated tau levels were comparable between the two strains of mice within the
injured group (Figure 11). Similarly, both groups of injured mice had increased levels of
Iba1 reactivity and comparable GFAP reactivity (Figure 13). Another set of MAPT KI
and C57BL/6 mice were naturally aged to 12-14 months old. When analyzing the silver
staining aged males and females had minimal positive silver staining which was
comparable between the two strains (Figure 10).

However, when investigating the

pathologically phosphorylated tau, aged MAPT KI male and female mice had greater
AT8 staining compared to their C57BL/6 counterparts (Figure 12). When analyzing the
staining for the Iba1 and GFAP, there was minimal Iba1 staining and moderate GFAP
staining for both aged MAPT KI and C57BL/6 animals (Figure 14).
When this data is considered together, we conclude that the MAPT KI mice should be
used for rmTBI studies over the C57BL/6 mice due to the observation that just as in aged
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humans, abnormal tau phosphorylations increase with age in the MAPT KI mice. This
observation may be attributed to the tau isoforms expressed in C57BL/6 and the MAPT
KI mice. The C57BL/6 mice, do not express any 3R tau isoforms once adulthood is
reached, with matured neurons expressing solely the 4R tau isoforms (Götz et al., 1995;
Spillantini & Goedert, 1998). Adult human brains express all six tau isoforms, where
both 3R and 4R isoforms are expressed equally at a ratio of approximately 1:1 (M
Goedert & Jakes, 1990; Hanes et al., 2009). There are also some sequence differences
between human and mouse tau that should be taken into consideration due to the fact that
these sequence differences can have implications for tau function. For example, the Nterminal region of human tau contains 11 amino acids that are lacking in mouse tau
(Hernández et al., 2020). This variation in the length of the N-terminal region has an
impact on the potential for tau to form the “paperclip” formation, with the longer human
tau more likely to form this conformation that its mouse tau counterparts.

The

“paperclip” conformation involves the folding of the C- and N-terminal ends into the
microtubule binding repeat domains. One study combined FRET pair mutants with
various phospho-mimicking mutations, known to be hyperphosphorylated in AD (AT8,
PHF1, AT100), in order to investigate the global folding of tau and how the level of
phosphorylation influences this folding and subsequent conformations (Jeganathan et al.,
2008). It was determined that the compaction of the paperclip conformation reacted
positively with the MC1 antibody, an antibody that recognizes pathological
conformations of tau in the early stages of AD, suggesting that this conformation of tau is
in fact pathological.
Improvements in the analysis of both the silver staining and immunohistochemistry could
be implemented in the future. In this study, qualitative analysis was conducted, in which
the sections were visually examined for positive staining. This approach was used seeing
as the quantified data would have been variable due to the inconsistent injuries.
However, using both qualitative and quantitative data would be desirable once the study
has been repeated. One could use a computer-assisted image analysis system, similar to
Williams et al. (2006), in order to calculate the optical density (OD) of the silver staining
in the sections of interest (Williams et al., 2006). In terms of the immunohistochemical
staining, one could use a program such as ImageJ, in order to analyze the photos taken
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and calculate the percentage of positive staining in the sections of interest (Moszczynski
et al., 2019).

4.4

Characterization of the Behavioural Outcomes triggered
by rmTBI

The final aim of this study was to characterize the effect of rmTBI on the behaviour of
MAPT KI mice using the Elevated Plus Maze (EPM) (to test for anxiety/anxiety-like
behaviours) and the Morris Water Maze (MWM) (to test for spatial learning/memory). In
terms of the EPM, injured male MAPT KI mice spent significantly more time in the
closed arms compared to the shams, although this difference was small; whereas, there
were no significant differences seen in the behaviours in the female MAPT KI mice
(Figure 15). During the Probe Trial of the MWM, there were no significant differences
in the amount of time spent in the target versus non-target quadrants for both the male
and female MAPT KI mice (Figure 17), although a trend can be seen for the male and
female shams to spend more time in the target quadrant. Unfortunately, during this
study, COVID-19 interrupted the progression of this work and the numbers of mice in the
colonies had to be decreased, meaning that we did not have the desired numbers for the
behavioural studies. Coupled with the fact that the CCI device was malfunctioning, one
must not over-analyze these results.

Ideally, these experiments would have been

replicated with higher n’s and with a fully functioning CCI device. However, these
results (the increased anxiety, as seen in the rmTBI males of the EPM, and trends for
troubled spatial cognition seen in the rmTBI males/females in the MWM), do agree with
other studies investigating the effects of rmTBI on behaviour post-injury (Broussard et
al., 2018; W. H. Cheng et al., 2019). One study testing the hypothesis that rmTBI
negatively impacts spatial memory and anxiety/anxiety-like behaviours suggested that
rmTBI does indeed impair spatial memory, as assessed by the MWM, and increases
anxiety/anxiety-like behaviours, as assessed by the EPM and the Open Field Tests (OFT)
(Broussard et al., 2018). Another study utilizing the Closed-Head Impact Model of
Engineered Rotational Acceleration (CHIMERA) model of rmTBI found that there were
deficits in the Barnes Maze (BM), another test of spatial learning and memory; however,
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contrary to this study, there were decreases in anxiety levels in the EPM coinciding with
increased risk taking behaviour (W. H. Cheng et al., 2019).

4.5

Caveats of the Novel Mouse Model

This new mouse model presents potential caveats that should be considered. First, with
the humanization of the tau gene, there is concern that the mice do not develop normally
as they age. Second, there is the potential for other abnormalities to present themselves
as the animals age, for example, poor interaction of the human tau with the other mouse
proteins or accelerated neurodegeneration. However, there are currently a few papers
published using these mice that can ease the concerns surrounding these potential
limitations. The first study that generated these mice found that neuroinflammation, cell
death, and overall brain atrophy were not altered or accelerated with the humanization of
the tau gene in mice aged to 24 months (Hashimoto et al., 2019). The second paper to
utilize these mice checked to see if the humanized tau protein was properly integrated
into the nervous system of the mice. This study found that the humanized tau protein was
properly integrated into the nervous system, as it was localized in the axons of the
neurons, similar to that of the wild type mice (Saito et al, 2019).

4.6

Conclusions

The results of this study support the use of MAPT KI mice for rmTBI studies.
Implications of this study for the future could include applying these results in preclinical
trials studying the pathophysiological mechanisms activated during recovery from
rmTBI. This model could also serve useful for testing inhibitors of GSK3β activity in a
more clinically relevant model, as human tau is more prone to pathological processes
compared to wild type mouse tau. The MAPT KI mice can also be humanized further by
targeting other genes of interest, such as β-amyloid, and mimicking the protocols used to
humanize the tau gene.

4.7

Significance

Currently, CTE can only be properly diagnosed post-mortem (Turner et al, 2013), which
is of no use to the individuals whose lives have already been lost. In order to improve the
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lives of those affected by neurodegenerative diseases such as CTE, and those of their
families/loved ones, studies must turn their attention towards the mechanisms and
pathways that initiate the detrimental cascades, leading to the development of the disease.
The number of people being affected by repetitive mild traumatic brain injuries is on the
rise, leading to an increase in the number of individuals developing CTE, additionally,
causing an increase in the burden/cost to health care systems (Luo et al., 2014). In order
to effectively develop a treatment, the time course of pathological activity and
contributing processes must first be established. The time of treatment administration
could then be designed to coincide with the time of peak pathological activity post-injury.
For example, correctly timed administration of a GSK3β inhibitor might be predicted to
prevent

the

abnormal

phosphorylation

of

tau,

the

formation

of

tau

aggregates/fibrils/tangles, and potentially the development of CTE later in life. This work
is of significant value to both the health and scientific communities since it is one of the
first, if not the very first, of its kind to explore concussion and tau pathology in a
clinically relevant model of concussion using transgenic mice solely expressing human
tau. This study will hopefully serve as a stepping stone for future preclinical studies of
rmTBI with a focus on pathophysiology and potential therapeutics.
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